roche annual report business report part innovate healthcareinnovative solutions spanning healthcare spectrum combined capabilities diagnostics pharmaceuticals enable us meet needs across entire healthcare spectrum identifying disease suscep tibilities screening disease atrisk populations prevention diagnosis therapy treatment monitoring innovative products advancing fight disease wide range fronts making real difference patients health professionals roche commitment innovating healthcare matched commitment corporate social responsibility sustainability one companys guiding values recognise economic social environmental concerns inter twined progress sectors requires progress three researchintensive company longterm strategic focus roche strives deliver sustainable value major stakeholderspredisposition table contents good know medication really help business report key figures year brief letter chairman roche group early detection group results outlook couldnt stood group strategy theuncertainty longer pharmaceuticals pharmaceuticals division brief results therapeutic areas research development prevention rd pipeline expanding biotech production medication helps capacity myosteoporosisand access medicines totake amonth diagnostics diagnostics division brief results business areas diagnosis research development key product launches scheduled suddenly realised life washanging thread access diagnostics board directors corporate executive committee corporate governance board directors corporate executive committee therapy pages corporate governance responsible feeling regained sustainable management control disease gave ahuge psychological lift dialogue stakeholders commitment employees commitment society monitoring safety health ive got independence back environmental protection assurance track record outlook key performance indicators gri reference list roche global market presence business report key figures roche group change mchf mchf chf lc sales sales research development operating profit exceptional items net income net cash equity change equity ratio core earnings per share chf dividend per sharein chf number employees dec continuing businesses proposed board directors lc local currencies price development nonvoting equ ity security genussschein chf roche nonvoting equity security adjusted swiss market index rebased business report year brief group roche group increases sales billion swiss francs record high billion swiss francs operating profit margin percentage points net income virtually level year despite income billion swiss francs divested consumer health business group awarded credit ratings aa standard poors aa moodys roche reselected inclusion dow jones sustainability indexes board propose th consecutive dividend increase swiss francs per share nonvoting equity security pharmaceuticals pharmaceutical sales advance four times global market growth rate sales anticancer drugs billion swiss francs strengthening roches market leadership oncology tamiflu production expanded significantly meet huge need pandemic readiness supplies positive results phase iii clinical trials rheumatoid arthritis breast lung pancreatic cancers diagnostics roche diagnostics maintains global market leadership sales growth operating profit remains previous years record level margin slightly next generation accuchek diabetes management products launched worldwide outlook abovemarket sales growth doubledigit increases roche group pharmaceuticals division core earnings per share growth target line sales growth visit httpwwwrochecom additional information roche growth rates based local currencies operating profit margins stated exceptional items business report letter chairman franz b humer verwaltungsratsprsident und ceo company outstanding innovative diagnostics division maintained leadership roche medicines diagnostics helped advance position difficult marketbut fell slightly short fight serious diseases operationally ofits performance goals financially group posted strong results substantial market share gains group operating profit exceptional items significant improvement operating profitability rose onethird record high billion swiss general meeting shareholders board francsat billion swiss francsnet income came directors propose dividend increase close matching previous years figuredespite swiss francs per share nonvoting income billion swiss francs recorded equity securityifapprovedthis thegroups divested consumer health business nineteenth dividend increase many years strong earnings performance enable us con tinue investing heavily research develop sales roche group rose local curren ment expanding production basewith cies first time exceeded billion swiss group expenditure research development francs pharmaceuticals division accounted totalling billion swiss francs annu increaseits sales allyours isone ofthe worlds researchinten yearfour times average market growth rate sive companies next several years business report letter chairman additionally investing billion swiss increase prescriptions existing francs new biotech manufacturing facilities drugs last year roche captured attention keep pace rising demand products health professionals public exciting new clinical datathese include data show roche excellent financial health ing herceptin make significant difference strengthened balance sheet signifi earlystage treatment aggressive breast cantly increased net cashover last three years cancers clinical trials involving nearly ratio equity total assets risen steadily women adding herceptin standard therapy increased financial strength halved risk ofcancer recurrence compared gives us strategic flexibility selectively expand standard therapy aloneand trial ofmabthera core pharmaceuticals diagnostics busi rituxan lymphoma patients maintenance nessesin late standard poors moodys therapy drug shown increase sur awarded roche credit ratings aa aa vival dramatically tide may also respectively second highest ratings assigned turning battle certain forms agencies disease claim like would unthinkable years ago pharmaceuticals division best year roche history despite expiry examples illustrate drug research us patent rocephin roches topselling development stop soon medicinethe division increased sales truly drug approved first indicationtaking impressive billion swiss francs billion development ofanticancer drugs new level swiss francs first time ever seven roche one core missions global research medicines generated annual sales organisation billion swiss francs cases signifi cantly morethe divisions operating profit margin also made significant progress projects exceptional items also showed another sig develop novel biotherapeutics rheumatoid arthri nificant improvement advancing tisa common disease characterised progressive inflammation cases progressive destruction joints clinical trial data powerful oncology portfolio key driver confirmed topselling anticancer medi behind superb results roche cine mabtherarituxan offers completely new healthcare company five medicines cancer approach treating rheumatoid arthritis market shown increase product developed chugai sub patient survival within space division also shown clinical trials yearsa new generation ofmore targetedless toxic slow joint damage significantly dramatically anticancer medicines made roche global improve diseases painfuldisabling symptoms market leader oncology reinforced chances good believe roche leadership last year sales growth soon major player disease area innovative new additions oncology portfolio avastin colorectal cancer tarceva lung responding threat potential flu pan cancer already well established demic one years greatest challenges roche acted energetically responsibly new roche medicines also launched success meet increased global demand leading fully therapeutic areasand supplemental influenza drug tamiflu among steps approvals new indications spurred significant promptly initiated massive scaleup pro business report letter chairman duction capacity risk adopted dna microarray test doctors gauge pricing policy provides significant discounts patients ability metabolise certain drugs based deliveries ofthe drug pandemic useand patients genetic profile information given five million packs oftamiflu help guide drug selection dosing deci world health organization rapid response sionsadditional dna microarray testsfor cancer stockpile use epicentre ofa potential pan screeningare currently latestage development demic help establish regional stockpiles druginadditionwe granted first sub reflecting groups strong performance licences production drug pandemic created new jobs last yearbringing total use holding indepth talks dozen number roche employees worldwide companies could provide additional manufac would like take opportunity turing support ifnecessary express thanks people dedi cation professionalism value create roche diagnostics year focused every working day vital ifroche continue launching new products particularly diabetes invest developing innovative solutions areas managementand also year ofunmet medical needby helping make patient division expanded markets never care effectiveand hence costefficient competed notably dna sequencingwhile clinically differentiated medicines diag market conditions continue difficult roche nostics play increasingly important role diagnostics maintained leading market posi easing pressure healthcare budgets tionwith sales advancing local currencies billion swiss francs divisions immuno decades roche actively committed diagnostics molecular diagnostics portfolios socially environmentally sustainable develop main growth drivers mentas well delivering longterm benefits patientsat end last year roche diagnostics posted operating profit reselected inclusion dow jones sustain billion swiss francs exceptional items ability indexes ftsegood indexwe matching alltime high previous year also ranked second pharmaceutical industry divisional profitability remained high category tribute sustainability industrydespite slight decrease operating efforts something pleased profit marginto strong pricing pressures equally pleased several highly respected production startup costs costs related publications including fortune science many new products launches year included us lists best companies main reasons decline work global market leaderwe feel obli roche always striven responsible cor gation supply advanced diagnostics make porate citizen well healthcare innovator significant contribution effective costefficient action taking ensure availability patient care new generation accuchek tamiflu event pandemic recent products improved diabetes management example ofhow seriously take wider respon began launching worldwide inis sibilities companywe also set high standards perfect case point response also policies practices regarding trans strong tothe european us launches ofour parency clinical researchwe disclose negative amplichip cyp test product takes us well positive results latestage trials another step closer personalised medicineusing early last year also began publishing data business report letter chairman clinical trials internetin addi tion roche established independently hosted publicly accessible online trial protocol registry provides information clearsimple language commitment corporate social responsibility also extends worlds least developed coun triesours one companies still research hivaidsand also one ofthe companies supplies medicines cost enforce patent rights poorest developing countriesin additionin early announced would provide technical expertise manufacture aids drug saquinavir inter ested manufacturers least developed countries cost clearly greatest contribution make sustainability continue developing new better solutions unmet medical needs also recognise continued viability suc cess innovative company depend business socially environmentally respon sible way outlook remains positive thanks portfolio innovative products well positioned continue creating value expect divisions achieve abovemarket sales growth local currenciesand target core earnings per share rise line group sales franz bhumer business report good know medication really help business report novel test brings personalised medicine closer british scientist anneke westra diagnosed manic depression start tenyear nightmare doctors prescribed succession drugs serious adverse reactions even caused hallucinations blackoutsthough anneke fighting depression life hadnt let stop earning phd biotech nology registering patent giving lectures world medicines left feeling drained worn one point even attempted suicide obviously things couldnt go like anneke began investigating ownthats found amplichip cyp test test predict peoples ability metabolise certain drugs annekes case test showed body breaking clearing medicines slowly allowing accumulate harmfully high levels nothing give anneke back lost years test results enable doctor adjust medication dosage works anneke treated lowdose combination three medicines finally feels fine predisposition cytochrome p genes code drugmetabolising enzymes found primarily liver amplichip cyp test detects variations two genes make patient poor rapid metaboliser many widely prescribed drugs infor mation help physicians make better personalised drug selection dosing decisions patients means effective treatment fewer side effects business report roche group group results operating activities taxes increased billion swiss francs roche group posted strong operating results group sales increased significantly net financial income showed significant improve billion swiss francsa gain local ment last year thanks groups strong currencies swiss francs us dollars positive cash flow restructuring group pharmaceuticals division key growth debt carried cut recent years driver sales increased four times fast roche posted positive financial result theglobal market average significantly ahead net income financial assets foreign growth rates north america europe exchange management exceeding financing costs japanthe divisions three important markets million swiss francs diagnostics division sales local currencies increased line global market growth billion swiss francsgroup net income nearly high year billion swiss strong topline growth positive impact francs despite income billion swiss francs groups earnings performance divested consumer health business operating profit exceptional items rose groups return sales margin local currencies billion swiss francsand corresponding operating profit margin improved significant improvement substantiallyrising percentage points groups financial positionthe ratio equity excellent sales growth year total assets total offset significantly increased investments assets financed longterm launch prelaunch activities groups strong development pipelines first time theoperating results restated prior outlook year figures include costs groups equity compensation plans employees barring unforeseen eventsroche reaffirms posi recorded operating expense groups tive outlook sales pharmaceu improved earnings performance primarily reflects ticals diagnostics division expected pharmaceuticals divisions significantly higher grow ahead ofthe market local currenciesand operating profit margin anticipate continued doubledigit growth pharmaceuticals division group whole diagnostics divisions operating profit exceptional items decreased local currencies sales growth expected stronger billion swiss francs resulting margin second halfofthe year firstthe reasons decline percentage points include patent expiries rocephin primarily due heavy price pressure market copegus fact expanded produc startup costs new manufacturing facilitiesthe tion capacity tamiflu result increase many new products launched year deliveries pandemic supplies drug higher depreciation increased volume second halfofour target core earnings instrument placements per share nonvoting equity security grow line sales despite significant investments groups strong profitability also reflected launch new products major new key figures ebitda rose local cur indications established products rencies billion swiss francsand cash flows business report roche group group strategy pharmaceuticals diagnostics businesses including majority shareholdings genentech healthcare st century chugai hub roche innovation network diagnostics evolving consumer needs innovation market pharmaceuticals company capitalise dynamics likely key drivers change broad synergies research development healthcare years aheaddespite enormous marketing capabilities augmented progress fight diseasethere still technology collaborations constellation many areas high unmet medical needand alliances develop individual products demand new better healthcare products product portfolios andservices bound grow result ofpopula tion ageing demographic changes biotechnology important factor inno advances occurred science technol vation strategy thanks early involvement ogy recent years clearly implications major investments sectorbiologics cur clinical practiceraising hopes may one day rently account approximately half roches better treatments mankinds serious revenuesthe group owns significant proportion diseases perhaps even ways preventing ofthe worlds biotechnology manufacturing capac curing thembut demand healthcare grows ity worlds leading producer pressures control costswhich may therapeutic proteins monoclonal antibodies unintended effect hampering innova tion creating value today tomorrow distinctive strategy business model focused creating sustain able value stakeholdersnot roches major divestments last several shareholders also patients employees yearsmost recently sale ofthe consumer health society largewe currently developing businesshave aimed focusing groups framework measuring value create energies entirely two innovationintensive ofthese constituenciesand expect divisionspharmaceuticals diagnosticstodays place time annual report roche highly focused companyand result well positioned industry pioneer healthcare predisposition testing prevention diagnosis therapy treatment monitoringroche market leader oncology transplantation virology world leader vitro diagnostics roche aspires distinctive ability drive value creation discoverydevelopment commercialisation medically differentiated products specifically roche pursuing industry leadership emerging field ofperson alised healthcare gaining importance advances areas genetic profiling enableearlier diagnosis facilitate better patient stratification clinical eco nomic benefits preventive therapies targeted medicines appeal consumers payers regulators well business report roche group creating value stakeholders innovative innovation words worked awfully hard everybodys innovator william burns ceo division roche pharmaceu nowadays claims ticals heino von prondzynski ceo division william burns idea innovation roche diagnostics erich hunziker cfo healthcare centres patientto genuine talk roches strategy implemen advancea new medicine diagnostic meet tation patients needs better anything else thats available certainly costconscious times witnessed mounting pressures control payers needs addressed healthcare spending several companies believe needs payersand healthcare hurt safety concerns highprofile prod systems whole met effectively ucts healthcare sector experienced addressing patientsneedsat roche pharmaceuti slowdown growth roches sales contrast cals use phrase clinically differentiated continued grow strongly com medicineto describe drugs treat particular pany premium stock market rating patient population significantly higher makes roche different degree success fewer side effects erich hunziker roche strategy designed optionsor simply much easier takewe help excel todays costconscious healthcare five anticancer medicines proven extend market market leader highgrowth patientslives claim healthcare com areas like oncology transplantation hepatitis pany match exactly kinds world leader vitro diagnosticsour aim products supply innovative prescription drugs diag nostics bestinclass heino von prondzynski roche supplies pioneer develop metoo drugs offering marginal benefits ing diagnostic devices wide range uses whats already marketand predisposition screening early detection interest following competitors response monitoring prognostic testing generics businessalsoinvestors becoming contribute better medical deci increasingly riskaversewhich means theyre pay sionmaking right line helping doctors ing close attention procedures companies make better decisions faster virtually every stage place risk management sustainabil fight disease promote ity includes areas like corporate governance meaningful savings time substan patentsaccess products poorest develop tially improving patient outcomes ing countries ethics businessthanks sound policies procedures transparent already leader major segments like reporting roche come recognised molecular diagnostics diabetes monitoring leader corporate sustainability pioneering work biomarkers cancer heart attack eh different ways degrees ofaspiring innovatorat roche weve embraced inno vation greatest strengththe core ofour com petitive advantage weve put innovation model place thats like industry innovator obviously access cuttingedge science technologywe got biotechnology early onacquiring major ity stake genentech back even could see potential protein thera peutics end business report roche group technological advances certainly one major drivers innovation role biotechnology play innovation process roche wmb understanding ofthe molecular basis ofdisease growsits increasingly clear diseases like cancerand even diabetesare far diverse anyone suspected may sound like discouraging newsits fact cause hopebecause means likelihood ofiden tifying optimal molecular targets new drugs increasing biotechnology opened com pletely new therapeutic approachesparticularly oncology pursuing new possibilities aggressively confident william burns ceo division roche pharmaceuticals bea major source offuture innovations course means also expect key growth driver us doesnt mean intend stop working new chemical therapeu tics meansour chances ofdeveloping truly differentiated medicines greatest wmb twin focus pharmaceuticals drug discovery efforts include small molecules diagnostics continue serve us well proteins future particularly given industry trend away one size fits allproducts individu eh one roches great strengths ability alised therapeutic options trendi might addin craft longterm strategy follow roche clearly leader clinically lead biotechnology result strategic documented therapeutic benefits increasingly choices made course last ten count strengths biotechnology years unique innovation model combin unique research network lead diagnos ing strong inhouse rdmajority shareholdings tics rd major competitive advantages genentech chugai partnerships scores biotechs universities gives us personalised medicine reality broad access technologies spur innova hvp seemed like distant vision years tionwere already major player biotechnology ago coming within reachroche already poised become even stronger launched worlds first commercially available pharmacogenomic test amplichip cyp strategic rationale behind roches test helps physicians select medicines commitment diagnostics industry dosages suitable patientsone ofthe clearly less dynamic pharmaceuticals key technologies powering test poly hvp right roche diagnostics fore merase chain reactionor pcrfor shortthe front ofanother revolution medicineour prod dna microarray developing ucts helping address two ofhealthcares microarraybased tests diagnosis moni critical challengesnamelydrug safety efficacy toring cancer osteoporosis complex one hand cost containment diseases particularly oncology aim otheras personalised medicine comes age enable treatments tailored closely certainly roches combined expertise genetic profiles ofspecific patient populationsour diagnostics therapeutics play key role leukemia microarrayfor examplewill major inpioneering new medical breakthroughs step forward discriminating leukemia subtypes quickly reliablyand amplichip p test could one day help physicians reliably business report roche group focusing highend medical innovations commercially risky given huge investments involved inherent uncertainty rd roche counterbalance risks eh despite heavy investments rdproduction marketingthere guarantees success generally speaking well continue pursue rather conservative financial investment strategy since helps counterbalance commercial risks associated hightech operating busi nesses wmb maintaining right balance house external rd innovation network erich hunziker chief financial officer viewed kind ofrisk spreadingstrategy majority stakes genentech chugai many alliances partnerships comple ment augment internal capabilities variety ofwaysamong thingsby reinforcing corporate culture promotes creativityand determine aggressive cancer decide course significantly enhanced depth therapies work ones wont quality development pipelinewhich important aspect risk managementwe need wmb divisions working together continue refining structures skills biomarkers several years biomarkers enabled us build manage innova potential increase understanding tion network successfullywe need ensure drug efficacy safety heino indi capabilities recognise promising cated theyre playing increasingly significant emerging technologies early well role drug discovery development partnership governance structures instance currently collaborating continue make us preferred partner product colleagues diagnostics biomarker technology alliances predict patients rheumatoid arthritis likely benefit treatment right roche enjoying strong operating mabtherarituxan actemra rheumatoid earnings expects continue arthritis emerging area ofstrength roche propose cash given growing range treatment options priorities rheumatoid arthritisit would extremely useful eh repaying debt increasing net liquidity test predicts different patients high list financial prioritiesand cer might respond different drugs personalising tainly ofour strong cash flow go medicine also means developing targeted good balance sheet currently iswe want drugsat present pursuing development make even betterwhich give us greater flexi cancer drugs adjuvant use aggressively bility strengthen core businessesand well arent palliative treatments longer continue make carefully selected acquisitions moving extending patients lives curing primarily strengthen group strategically cancersdespite recent advanceshoweverthe war gain access new technologies thats cancer stillunfortunatelyfar financial resources goal isnt max imise quarterly earnings never never bethats trap weve managed avoid would odds long development cycles businesses business report roche group hvp healthcare market change signifi cantly next decade ways fairly easy predictageing populations pop ulation growth certain fuel demand healthcarewhile increasing pressure contain costsand seems equally certain person alised medicine become growing part mainstream medical practiceten years want company consistently brings clinically differentiated products services marketand want acknowledged regu lators payers company steady eye delivering benefits justify costs distinctive combination strengths gives us strategic edge enabling us develop novel heino von prondzynski ceo division roche diagnostics products services spanning entire health care spectrum believe im provements every step healthcare process starting predisposition screening early detection roche well carry making significant contributions fronts wmb achieving ambitions require us continue strong financial commitment research development something every intention ofdoingworldclass research backbone ofour strategy ofcreating value innovationits enables us deliver advances healthcare creating superior value patients stakeholdersand means well keep especially close eye new emerging developments science technology continue anticipate trends adjust refine strategy accord ingly end business report couldnt stood uncertainty longer business report test hiv spared two parents months worry healthy baby first words parents want hear birth child ruth colin webb differentthe british couple hivpositive daughters bornthere time webbs would wait agonising months daughters births find whether girls hivthats long took less sensitive tests used time detect virus childs body hivpositive mothers like ruth webb make huge effort give birth healthy childrento reduce risk mothertochild transmission ruth took fortovase pregnancies lower amount hiv blood doctor closely tracked viral load hiv monitoring test way knowing whether babies would alright born least spared addi tional months anxious waiting hiv dna test provided initial reassur ance within weeks birth webbs girls test results enormous relief sarah anna five seven years old hivnegative early diagnosis pcrbased tests detect even tiny amounts hiv making possible diagnose infection long symptoms appear besides resolving uncertainties perinatal hiv transmission give hivpositive patients doctors critical timeadvantage fighting virus earlier therapy started better business report pharmaceuticals division brief sales millions chf operating profit exceptional items millions chf including charges equity compensation plans number employees key figures change change millions chf chf local currencies sales sales roche pharmaceuticals genentech chugai ebitda operating profit research development exceptional items pharma executive committee january william burns ceo division roche pharmaceuticals george c abercrombie north america jennifer allerton informatics eduard holdener development peter hug partnering jonathan kc knowles research dominic moorhead finance controlling paul newtonsyms human resources charles sabbah strategic marketing pascal soriot claude schreiner western europe jan van koeveringe technical operations february march business report pharmaceuticals results sales region pharmaceuticals division recorded best result ever exceeding high abovemarket growth previous year sales full latin america year rose local currencies swiss japan francs us dollars billion swiss others francsfour times fast global marketthe gains also offset decline groups former topselling medicine rocephin europe following expiry us patent julyas north america growth driven primarily strong demand divisions flagship oncology port folionow boosted innovative cancer treat italic growth rates ments avastin tarceva strong sales cellcept transplantation pegasys hepatitis b c antiinfluenza drug tamiflu therapeutic areas many governments stockpiling part pan demic readiness programmes also contributed oncology growth divisions oncology transplantation virology franchises significantly outpaced cancer one ofthe main causes ofdeath indus respective markets trialised countries roche group forefront search better solutions operating profit exceptional items increased patients physicians important area againby billion swiss francsthe oper unmet medical needroche pioneering number ating profit margin exceptional items gained ofadvances cancer treatmentincluding targeted percentage points rising therapy mabtherarituxan herceptin avastin improvement achieved tarceva xeloda examples roche despite higher investments rd continued groups innovative cancer treatments product launch activities andby comparison much lower gains product divestments two thousand five outstanding year ebitda totalled billion swiss francs forthe roche groups oncology portfoliosales salescompared previous year oncology products grew account oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen neorecormon roferona neutrogin picibanil vesanoid unless otherwise stated growth rates local currencies business report pharmaceuticals sales therapeutic area breast cancer common cancer among women worldwide million women newly diagnosed almost dying disease year different types transplantation breast cancer knowledge tumour charac dermatology teristics essential determining appropriate metabolic disorders treatment herceptin trastuzumab designed central nervous system specifically particularly aggressive type tumour herpositive accounts approx infectious diseases imately breast cancers sales herceptin targeted treatment approved cardiovascular diseases herpositive breast cancershowed impressive inflammatory diseases gains key markets strong growth bone diseases us europe driven extensions virology treatment duration increased firstline others penetration herceptin also supported anemia considerable growing body clinical data oncology showing product offers significant survival benefits advanced early disease settings result strong data reported divisional salesall major brands con herceptin already used reimbursed tributed result substantially countries adjuvant early disease reinforced groups position worlds lead setting advance approval see also major ing provider ofcancer medications development activitiesoncologypsetting new standards cancer treatment p patient nonhodgkins lymphoma nhl group storyp malignancies lymphatic system affects approximately million people worldwide skeletal complications including hypercalcemia claims estimated lives yearsales bone lesions fractures often associated mabtherarituxan rituximabfor treatment cancer following rollout bondronat indolent aggressive forms nhl ibandronic acid major european markets strong throughout yeardriven steady rise prevention skeletal events patients prescriptions forms ofnhl europe breast cancer bone metastasessales increased august genentech biogen idec filed sup stronglyby million swiss francs plemental application us food drug administration fda approval product colorectal cancer cancer large intestine use untreated patients intermediate rectum accounts million new cases grade aggressive nhl pivotal international around newly diagnosed cancers phase iii clinical trial shown two years worldwide yearit second mostcommon maintenance therapy mabtherarituxan cause cancer deaths europethe main treat dramatically improves chances survival ment surgerywhich may also combined patients suffering indolent nonhodgkins radiotherapy chemotherapy lymphoma regardless initial therapy based results roche filed application avastin bevacizumab first antiangiogenic eu regulators december expand drug treatment cancer generated products indications include maintenance treat impressive billion swiss francs sales first ment patients indolent nhl see major full year marketalready approved us development activities pp information treatment advanced colorectal cancer ongoing clinical development programmes avastin received eu approval indica mabtherarituxan products tion january launched business report pharmaceuticals oncology professionals moved asco oncology specialists professionals attended st american society clinical oncology asco meeting orlando florida last may also present jonas marques oncologyhematology sales manager roche brazil particularly interested special session avastin herceptin products featured packed session clearly moved attendees considered studies presented extremely important impact consistent findings cancers colorectal currently awaiting herceptin presentation one worlds leading approval brazil oncologists remarked biology spoken must listen added herceptin ushered attendees responded standing ovation new era breast cancer treatment first time seen type data presentation says jonas think says lot presentations impact evident ses impact products cancer world sion says jonas one brazilian specialist called clinic prescribe herceptin adjuvant therapy jonas joined roche brazil oncology team patients already treated breast cancer always aware importance last six months work patient care herceptin presentation asco meeting given job new meaning oncologists also impressed data women herpositive breast cancer may avastin appears potential treatment real chance longterm survival key european marketssales us continue europepancreatic cancerone show rapid growthwhile uptake europe also aggressive malignancies kills higher proportion strongsee patient storyp ofpatients first year diagnosis cancerit often resistant chemotherapy sales xeloda capecitabine continued radiotherapy tends spread quickly strong upward trend impressive gains parts body pancreatic cancer major markets growth fuelled fifth leading cause cancer deaths devel recent us eu approvals use ofthe prod oped world tenth frequent cancer uct adjuvant treatment surgery ofcolon europewhere kills people per year cancer first full year market tarceva estimated million new cases annually erlotinib novel targeted cancer drug lung cancer common cancer worldwide proven survival benefit advanced nonsmall cell leading cause ofcancer deaths world lung cancer pancreatic cancergenerated robust business report pharmaceuticals salesmarket response product proven longterm organ patient survival positive following us approval late benefits zenapax daclizumab prevents second thirdline treatment nonsmall cell acute rejection newly transplanted organs lung cancerthe product received eu approval valcyte valganciclovir prevention indication september cytomegalovirus cmva dangerous infection already launched several european coun associated transplantation complete tries rollouts markets scheduled roche transplantation portfolio roche supports throughout november thefda approved basic transplantation research funding tarceva treatment advanced pancreatic independent roche organ transplantation cancera filing indication submitted research foundation eu regulators october roche group maintained global leadership anemia transplantation market groups transplantation portfolio generated total sales anemia occurs number ofred blood cells billion swiss francs rise falls normal starving organs tissues previous year immunosuppressant cellcept oxygen seen patients posted solid doubledigit gains globally impaired renal function due chronic kidney key regions maintaining leadership disease patients cancer mycophenolic acid market market share potential longterm effects anemia include despite entry ofa new competitor cardiovascular disease renal patients duced survival patients canceranemia valcytethe market leader prevention cmv fatal ifleft untreated disease showed consistent growth throughout year solid doubledigit gain recorded sales roches neorecormon chugais combined sales valcyte cymevene epogin epoetin betafor treatment ofanemia ganciclovir showed healthy growth neorecormon retained leadership position markets virology despite sustained pricing pressurewith indi cations cancerrelated anemia renal anemia liver one bodys important contributing increase sales organs performing vital functions oncology setting neorecormon continued hepatitis b c viruses hbvhcv cause strong market penetrationposting growth acute chronic liver diseasepotentially leading well ahead market thanks primarily liver failure cirrhosis cancer worldwide continued adoption convenient million people thought chronically weekly prefilled syringe formulationneorecormon infected hbv highly infectious pathogen indicated treatment anemia responsible estimated million deaths patients solid lymphoid cancers receiv annuallymore million people around ing form ofchemotherapy world infected hcvand million new cases occur yearhepatitis c main reason transplantation liver transplantation people worldwide receive lifesaving combined sales pegasys peginterferon alfaa organ transplants year thanks advances copegus ribavirin showed strong growth surgical procedures immunosuppressive particularhigher sales volumes europe therapy prevent organ rejection transplant driven market share increases market recipients survive many years expansion result ofnew indicationssignificant new organsthis means increased demand approvals towards end early effective lowtoxicity immunosuppressant drugs given pegasys plus copegus combi like cellcept mycophenolate mofetil nation broadest range ofhepatitis c indications business report pharmaceuticals meeting world demand tamiflu world health organization recom mends governments stockpile antivirals preparation possible influenza pandemic part overall pandemic plans roche assisting governments dramatically expand ing tamiflu production capacity respond critical need armin knoblich global supply chain leader tamiflu proud part international task force roche specialists working around clock ramp supply quickly able produce million treatments annually says extracted star anise plant native four expanding network suppliers thirdparty provinces china shikimic acid also pro manufacturers licensees selectively investing duced large quantities special fermentation facilities way meet demand method rely star anise expanding tamiflu keeping manufacturing network production shikimic acid fermentation roche flexible enough respond situation future helping ensure tamiflu production held back crop failure disruption new production processes also play role supply example shikimic acid starting material tamiflu product combination including use reserved use rapid response stockpile patients coinfected hiv contain influenza pandemic outbreak roche normal liver enzyme levels application continues substantially expand tamiflu pro approval ofcombined pegasys copegus hep duction capacity able produce atitis c chugai designated priority million treatments annually using review japanese authorities pegasys also collaborative network ofits facilities approved treatment hepatitis b ofa significant number ofindependent companies countries worldwide october roche announced willingness enter discussions governments worldwide sales tamiflu oseltamivir rose manufacturers production tamiflu billion swiss francsdriven severe influenza emergency pandemic use roche since signed season japan early year increased sublicensing agreements shanghai pharma orders pandemic readiness supplies ceuticals china hetero drugs india countries placed orders pandemic discussion twelve additional partners stocks tamiflu purchasing enough enhance tamiflu production network cover populations roche end year fda approved emea agreed donate five million packs oftamiflu swiss authorities recommended approval world health organization two product prevention influenza chil million packs kept regional stockpiles dren aged years see meeting world demand use event outbreaks avian influenza fortamifluaboveand access medicinesp andanother three million packs central storage business report pharmaceuticals major product approvals launches product generic name indication country avastin bevacizumab firstline treatment combination chemotherapy eu metastatic colorectal cancer bonvivaboniva ibandronic acid osteoporosis oral oncemonthly formulation eu usa switzerland osteoporosis intravenous formulation usa invirase saquinavir hiv disease mg formulation eu switzerland pegasys peginterferon alfaa chronic hepatitis b eu usa hcvhiv coinfection eu usa switzerland tarceva erlotinib second thirdline treatment advanced eu nonsmall cell lung cancer switzerland advanced pancreatic cancer combination usa gemcitabine xeloda capecitabine adjuvant colon cancer monotherapy eu usa switzerland includes supplemental indications updated january hiv worldwide pandemicand number primary care people living hiv continues risethe world health organization estimates million osteoporosis causes gradual loss ofbone density people including million children making bones brittle prone breakit affects living hivaids end offor millions people worldwide especially women almost years roches innovative drugs diag menopause nostic tests placed forefront ofefforts combat hiv infection aids bonvivaboniva ibandronic acid first continue working improve standard hiv oncemonthly oral bisphosphonate approved care worldwide information roches treatment ofpostmenopausal osteoporosis hivaids initiativessee access medicinesp launched roche copromotion part ensuring access healthcare worldwide pand ner glaxosmithkline us april visit wwwrochecom europe september sales totalled million swiss francs expected gain sales fuzeon enfuvirtide increased momentum physicians patients recognise million swiss francs helped data prefer simplicity convenience major studies showing added value oncemonthly tabletin january boniva injec fuzeon prescribed together latest tion became first intravenous medication antihiv agents recent updates key treatment approved us treatment post guidelines also support fuzeon use treatment menopausal osteoporosis providing proven experienced patients expected drive bonestrengthening benefits bisphosphonate uptake ofthe drug therapy women given every three months boniva injection designed meet needs ofpatients unable take tolerate oral bisphosphonatesthe eu authorities cur rently reviewing marketing application innovative formulation bonviva see patient storyp business report pharmaceuticals topselling pharmaceutical products roche group sales change product generic name indication millions chf local currencies mabtherarituxan rituximab nonhodgkins lymphoma neorecormon epogin epoetin beta anemia herceptin trastuzumab metastatic breast cancer cellcept mycophenolate mofetil transplantation avastin bevacizumab metastatic colorectal cancer tamiflu oseltamivir treatment prevention influenza b pegasys peginterferon alfaa hepatitis b c rocephin ceftriaxone bacterial infections xeloda capecitabine colorectal breast cancer xenical orlistat weight loss weight control kytril granisetron nausea vomiting induced chemotherapy radiation therapy following surgery nutropin protropin somatropin somatrem growth hormone deficiency xolair omalizumab asthma copegus ribavirin hepatitis c cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection pulmozyme dornase alfadnase cystic fibrosis tarceva erlotinib nonsmall cell lung cancer pancreatic cancer neutrogin lenograstim neutropenia associated chemotherapy dilatrend carvedilol chronic heart failure hypertension coronary artery disease activase tnkase alteplase tenecteplase myocardial infarction global sales xenical orlistat research development flat marketin products eu labeling expanded include data use ofthe product roche committed discovering develop obese adolescents xenical thus first ingclinically differentiated medicines key thera weightloss medication united states peutic areas including oncology inflammatory europe information label autoimmune bone diseasesvirology trans february existing agreement glaxo plantation broad interdisciplinary approach smithkline expanded include promotion made possible combined expertise prescription xenical us one ofgsks sales groups pharmaceuticals diagnostics divisions forcesin january fda advisory committee helping expand understanding ofdiseases recommended approval application filed biological processes translate scientific gsk last june market lowdose orlistat advances innovative medicinesinnovation overthecounter medicine weight loss science technology core roche groups focused rd strategy major products success strategy reflected rich expected sales rocephin ceftriaxone ness groups pharmaceuticals pipeline declined markedly following expiry ofthe prod strength expressed number ofnew ucts us patent july emergence ofgeneric molecular entities nmes rd portfolio competitors second halfofthe year success rate groups latestage clinical business report pharmaceuticals research projects major therapeutic areas expertise therapeutic antibody research december adds newcuttingedge technologies products roche rd organisation pipeline glycarts unique protein technology complements oncology efforts develop biological compounds offer neurological patients superior efficacy safety psychiatric diseases virology rd pipeline respiratory diseases genitourinary diseases end pharmaceuticals divisions inflammatory autoimmune rd pipeline comprised projects including bone diseases new molecular entities nmes addi cardiovascular tional indications fourteen nmes currently metabolic diseases phase phase phase ii five phase iii filed regulatory reviewin projects entered phase development entered phase ii entered phase iii seven projects moved ofthe rd portfolio following regula tory approvals roche pharmaceuticals currently projects trials fifteen offifteen phase iii trials preclinical research across seven therapeutic met clinical endpoints also makes roche areas development projects nine thera industry leaderthis due part selection deci peutic areas sions based aggressive screening thorough profiling ofcompounds discoverypreclinical four rochemanaged rd projects early clinical stages discontinued phase one reverted rd partner eight discontinued another cornerstone ofour rd strategy empha phase two reverting rd partners sises value leveraging key product assets two outlicensed three discontinued expanding use new indications phase ii one reverted partner mabtherarituxan case pointalready estab discontinuations phase iii lished cancer medicineit tested another important area unmet medical need partnering success rheumatoid arthritis see rheumatoid arthritis autoimmune diseasesp pursuing innovative strategic alliances com plement groups strong internal research roche continuing implement initiatives roche pharma partnering unit continued helping aim achieve better patient selection clinical build dynamic robust pharmaceuticals development programmes developing predic portfolio see partnering innovation p tive biomarkers key area collabora roche pharmaceuticals signed new tionbetween pharmaceuticals diagnostics licensing agreementsincluding six productrelated divisionstests enable predictions ofhow dif research technology partnershipsand ferent patients might respond particular drugs extended relationships longterm partners allow identification effective drug glaxosmithklineprotein design labs combinations patient subpopulations also evotec limiting undesirable effects acquisition glycart biotechnology com pleted july represents significant addition business report foldout rd pipeline cid pharmaceuticals therapeutic proteins building stronger portfolio biopharmaceuticals promising candidates innovative therapies number disease areas however creating proteinbased drugs complex process poses challenges different manufacturing small mole cules roche pharmaceuticals established therapeutic protein initiative tpi build expand expertise area tpi global initiative uniting contributions many divisional functions protein discovery development activities penzberg protein mulation basel cornerstones acquiring recombinant proteins especially monoclonal anti developing external internal knowledge bodies demonstrated value novel thera skills roche established novel technologies peutic agents due high target specificity cellline development automated product isolation already provide safe effective therapies advanced analytical technologies many patients says stephan fischer global head biologics research development roche since inception tpi helped increase expertise competence functions involved roche pharmaceuticals rd productivity protein research development manufacturing put number proteinbased projects rising four roche group unique position keep deliver key areas ing breakthrough medicines oncology inflammatory autoimmune disorders transplantation major development activities treatment adjuvant colon cancer advanced renal cell carcinoma pancreatic prostate oncology ovarian cancerit also tested combina major clinical development programmes tion tarceva nonsmall cell lung cancer exploring benefits mabtherarituxanher nsclc ceptin avastin tarceva xeloda additional important indications roche evaluating mabtherarituxan chronic lymphocytic leukemia cll two phase iii pro recent phase iii data shown avastin grammes exploring use firstline treatment significant survival benefit metastatic nonsmall therapy ofrelapsing cll cell lung cancer metastatic breast cancer increasing drugs potential become main phase iii iv trials herceptin ongoing stay cancer treatment see setting new standards metastatic adjuvant settings breast cancer treatment p regulatory filings cancer herceptin also evaluated new indications planned addi treatment gastric cancer data four large tionavastin studied phase iii trials clinical trials patients earlystage breast business report rd pipeline major development projects successfully brought forward therapeutic area project id projectproduct generic name pharmacological class indication phase partner cardiovascular r enzyme inhibitor type diabetes ii metabolic diseases r type diabetes r enzyme modulator type diabetes ii r type diabetes r type diabetes r dyslipidemia nippon shinyaku ns r cetp inhibitor dyslipidemia ii japan tobacco jtt r dyslipidemia r insulin sensitiser insulin sensitiser type diabetes ii genitourinary disease r overactive bladder r gpcr agonist male erectile dysfunction ii hematology r cera continous erythropoietin receptor activator cancerrelated anemia ii nephrology r cera continous erythropoietin receptor activator renal anemia iii inflammatory autoimmune r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate responders iii genentech biogen idec bone diseases r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis antitnf inadequate responders filed genentech biogen idec r valcyte valganciclovir inhibitor cmv replication ulcerative colitis r rheumatoid arthritis r kinase inhibitor rheumatoid arthritis ii r inflammatory bowel disease r actemra tocilizumab humanised antiil receptor monoclonal antibody rheumatoid arthritis iii chugai r actemra tocilizumab humanised antiil receptor monoclonal antibody systemic onset juvenile idiopathic arthritis iii chugai r humanised anticd monoclonal antibody rheumatoid arthritis ii genentech pro r osteoarthritis r autoimmune diseases transplantation biocryst r cellcept mycophenolate mofetil impdh inhibitor lupus nephritis iii aspreva r cellcept mycophenolate mofetil impdh inhibitor myasthenia gravis iii aspreva neurological r alzheimers disease psychiatric diseases r depression r schizophrenia r alzheimers disease r anxiety r schizophrenia oncology r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapsed iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line iii r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkins lymphoma maintenance filed genentech biogen idec r omnitarg pertuzumab antiher monoclonal antibody ovarian cancer ii genentech r omnitarg pertuzumab antiher monoclonal antibody metastatic breast cancer ii genentech r tarceva erlotinib egfr inhibitor glioblastoma multiforme ii genentech osi pharmaceuticals r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc st line maintenance iii genentech osi pharmaceuticals r erlotinib bevacizumab r tarceva erlotinib egfr inhibitor nsclc st line combo chemotherapy iii genentech osi pharmaceuticals r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc nd line iii genentech osi pharmaceuticals r erlotinib bevacizumab r tarceva erlotinib egfr inhibitor pancreatic cancer filed genentech osi pharmaceuticals r solid tumours r epothilone solid tumours ii kosan biosciences kos r solid tumours r solid tumours r monoclonal antibody metastatic breast cancer antisoma r humanised anticd monoclonal antibody hematologic malignancies genentech pro r epothilone solid tumours kosan biosciences kos r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo iii r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line extension iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer st line combo extension iii genentech r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma iii genentech r avastin bevacizumab antivegf monoclonal antibody nsclc st line iii genentech r avastin bevacizumab antivegf monoclonal antibody pancreatic cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody prostate cancer iii genentech r solid tumours r herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer combo hormonal therapy iii genentech r herceptin trastuzumab antiher monoclonal antibody adjuvant breast cancer iii genentech r herceptin trastuzumab antiher monoclonal antibody gastric cancer iii r bondronat ibandronic acid bisphosphonate metastatic bone pain iii respiratory diseases r daclizumab anticd monoclonal antibody asthma ii pdl biopharma r dual integrin antagonist asthma ii r nuclear receptor agonist emphysema ii transplantation r daclizumab anticd monoclonal antibody transplant maintenance pdl biopharma viral r hiv infectious diseases r antibiotic bacterial infections ii sankyo cs r hcv r hcv pharmasset r hcv maxygen r hcv pharmasset participation sg sigmart nicorandil acute heart failure filed chugai epoch epogin epoetin beta chemotherapyinduced anemia iii chs recombinant parathyroid hormone osteoporosis ii daiichi asubio pharma ed activated vitamin derivate osteoporosis iii avs antevas nicaraven hydroxyl radical scavenger subarachnoid hemorrhage filed cal humanised antipthrp monoclonal antibody bone metastases ii chc solid tumours cell therapeutics cgs femara letrozole aromatase inhibitor breast cancer filed novartis gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii val valine posthepatectomy ii participation raptiva efalizumab anticda antibody adult atopic dermatitis genentech lucentis ranibizumab antibody fragment vegf agerelated macular degeneration filed novartis ophthalmics xolair omalizumab antiige antibody pediatric asthma peanut allergy ii iii novartis tanox optin opportunities pro vegf topical vegf diabetic foot ulcer genentech brfc baff inhibitor rheumatoid arthritis genentech r mabtherarituxan rituximab anticd monoclonal antibody primary progressive multiple sclerosis iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody relapsed remitting multiple sclerosis ii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis ii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody ancaassociated vasculitis iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody systemic lupus erythematosus iii genentech biogen idec r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer ii genentech g topical hedgehog antagonist basal cell carcinoma genentech curis pro apoltrail cancer genentech r vascular targeting agent solid tumours ii antisoma dmxaa r ef modulator solid tumours arqule arq r glp glp type diabetes ii ipsen bim r calcineurin inhibitor renal transplant ii isotechnika isa r nonnucleoside reverse transcriptase inhibitor hiv medivir r alzheimers disease memory pharmaceuticals end pharmaceuticals divisions rd pipeline comprised projects including phase transition preclinical clinical development new molecular entities nmes additional indications fourteen nmes currently phase phase initial studies healthy volunteers possibly patients phase phase ii five phase iii filed regulatory review projects entered phase ii efficacy tolerability dosefinding studies patients phase development entered phase ii entered phase iii phase iiilargescale studies patients statistical confirmation ofsafety efficacy bluetype signifies first indication blacktype additional indications therapeutic protein current december small moleculepharmaceuticals partnering innovation partnering key element roches strategy develop innovative differentiated medicines patients pharma partnering pp com panys business development licensing department analyses external oppor tunities year find cuttingedge science complement roches rd roche find external innovation focus emerging innovative science says immunologist marketing veteran hari kumar one pps finders strategy teams tell us need drug condition effective treatment technology go look pps alliance directors take deal approved contract negotiated finders specialists combine scientific exper prepare roche projects integration ensure tise business acumen job identify communication partners open clear opportunities could lead new treatments including new uses existing roche products throughout process roche relies core part nering values flexibility respect partners culture finder identifies opportunity larger pp autonomy commitment sides team assesses based three key questions benefit collaboration organisationwide science viable differentiated opportunity partnering culture helps ensure continued access complement roches overall strategy com broad range external innovation expertise mercial potential senior management make decision based answers cancer adjuvant setting shown adding extensive latestage programmes studying xeloda herceptin chemotherapy significantly reduces adjuvant breast cancer combination risk cancer recurrence population chemotherapy adjuvant colon cancer setting us eu filings indication planned first secondline therapy metastatic first quarter colorectal cancer continuing recent interim analysis large collaborative group study tarcevaa human epidermal growth factor receptor drug firstline treatment advanced pancreatic heregfr inhibitor designed interfere cancer showed adding xeloda standard molecular signal plays significant role chemotherapy gemcitabine significantly extends tumour cell growth numerous types ofcancer patient survival improves quality oflife currently tested firstline adju vant nsclc settings combination headtohead phase iii study comparing bon avastin secondline nsclctarceva also dronat zoledronic acid treatment evaluated treatment glioblastoma multi metastatic bone pain commencedwith results formeone ofthe aggressive types ofprimary expected filings indication brain tumour planned us europe business report pharmaceuticals hematology nephrology anemia development actemra tocilizumab formerly clinical development ofcerathe first continuous mra ra progressing wellphase iii data erythropoietin receptor activator treatment japan presented american college anemia progressing track phase iii rheumatology meeting november show renal programme product includes six trials treatment actemra significantly reduces involving patients chronic kidney progression joint damage improves ra disease dialysis dialysisthe signs symptomsbased datachugai first four phase iii trials dialysis patients plans file marketing application actemra successfully completed end ofcera ra japan first half patient antianemia drug ever studied using long recruitment international phase iii trials pro dosing intervals every four weeks ceeding plannedregulatory filings us patients initial filingroche plans file mar eu expected chugai launched keting applications worldwide cera renal actemra japan first indicationcastlemans anemia roche view patent diseasea rare condition causes severe enlarge infringement litigation initiated amgen ment ofthe lymph nodes us impediment development launch ofcera united states cellcept developed collaboration aspreva pharmaceuticals autoimmune applica rheumatoid arthritis autoimmune diseases tions including treatment lupus nephritis rheumatoid arthritis ra autoimmune disor kidney complications associated autoim der characterised joint inflammation even mune disease lupus erythematosus myasthe treatedcan result progressive joint destruc nia gravis chronic autoimmune disease charac tion andultimatelyloss offunctionits exact cause terised episodes muscle weaknessphase iii unknownand yet curewithin two clinical trials drug indications years developing raup patients waycellcept first potential new treat xray evidence joint destructionand within ten ment either ofthese debilitating sometimes years unable work perform everyday fatal conditions many years january tasksra one common autoimmune cellcept designated orphan drug disorders thought affect mil treatment ofmyasthenia gravis fda lion people worldwidecurrent treatments include diseasemodifying antirheumatic drugs dmards diabetes biologic therapy antitnf drugs roche completed twoyear animal car cinogenicity programme insulin sensitiser roche significantly advanced devel rrequired fda members opment oftwo medicines potential sub class agentsa final decision commence stantially improve treatment ofra ment phase iii clinical testing compound type diabetes taken fda mabtherarituxan first selectively targeted agencies completed reviews bcell therapy studied diseasethe us carcinogenicity data eu filings august september products first rheumatoid arthritis indication rep two compounds developed resent significant milestonethe filingsbased treatment type diabetes moved phase ii data pivotal reflex trialcover use clinical testing glucokinase activator mabtherarituxan patients failed dipeptidyl peptidase dppiv inhibitor respond adequately current biologic therapies subgroup ra patients considered difficult treatpositive outcomes also seen phase iib clinical trial dancer patients previously failed treatment one dmards business report pharmaceuticals setting new standards cancer treatment st meeting american society clinical oncology asco orlando florida may roche partners presented data unprecedented eight major phase iii trials successfully met primary endpoints product generic name indication clinical trial benefit avastin bevacizumab metastatic hernegative breast cancer improvement overall survival st line treatment e metastatic nonsmall cell lung cancer improvement overall survival st line treatment e metastatic colorectal cancer reduction risk death nd line treatment e herceptin trastuzumab herpositive breast cancer adjuvant treatment reduction risk disease recurrence nsabp b ncctg n joint analysis herpositive breast cancer reduction risk disease recurrence adjuvant treatment hera mabtherarituxan relapsed indolent nhl improvement response rituximab maintenance treatment gslg duration years tarceva erlotinib pancreatic cancer st line treatment pa improvement overall survival expanding biotech production capacity oceanside california facility acquired genentech biogen idec last june currently roche group continued reconfigure converted produce avastinmanufacturing manufacturing capacities meet require ofbulk drug substance expected commence ments ofa changing product portfolio increase fda licensure expected first half efficiency global manufacturing opera ofin genentech received fda licensure tionsin particulara shift chemically derived new avastin manufacturing facility porrio active pharmaceutical ingredients towards biolog spain ics corresponding trend towards sterile liquid dosage forms driving current activities work new basel switzerland penzberg area technical development activities also reflect production facilities therapeutic antibodies impact pharmaceuticals divisions scheduled technical completion dynamic rd portfolio including development ismoving ahead planned inlicensed products roche ongoing pro jects reduce supply chain complexity andoptimise inventory levels remain track access medicines four major new facilities dedicated last year primary role roche pharmaceu new biotech production facilities epoetin ticals division discover develop com cera penzberg germany stateoftheart mercialise innovative medicines adoption packaging storage facility injectable drugs policies extend access critically needed mannheim germany plant high products people affected poverty throughout potency pharmaceutical products shanghaithe world integral part ofhealthcares mission new penzberg mannheim facilities therefore addition supporting local initia operational since middle ofthe shanghai tives expand healthcare accessroche imple facilitythe first ofits kind chinais scheduled mented patent pricing policies joined come stream yearit produce cellcept major international efforts aimed addressing xeloda chinese market problem business report pharmaceuticals roche file new patents medicines steps taken include implementing tiered pricing least developed countries defined system significant reductions pandemic unnor enforce patents already holds use licensing agreements local companies countries response devastating production drug pandemic use hivaids pandemic company extended india china addition taking unprece policy subsaharan africathe poorest dented steps ramp tamiflu production capac hardesthit region ity see meeting world demand tamiflu p roche working us national institute prices roche charges products low allergy infectious diseases international lowermiddle income countries virology experts expand information base corresponding prices switzerland launch regarding optimal use tamiflu roche supplies hiv medicines invirase hn avian influenza strain viracept profit least developed countries subsaharan africaas resultreduced prices access medicines issue affects products apply ofall people living developing world pose significant hivaids worldwide challenges industrialised countriesas wellin united statesfor exampleroche committed additionroche member ofthe accelerating making sure every patient needs roche access initiativewhich helping increasing num drug access itwhether patient senior bers ofhivaids patients developing countries citizen treated canceror member receive treatment company also supports working family facing organ transplant two hiv treatment access programmes roche patient assistance program established care programme four african countries first industry provide cambodian treatment access programme prescription drugs free charge qualifying addition providing fundingmedicines diag patients need lack prescription nostics programmesroche also coverage means pay contributed providing training hivaids care treatment hundreds healthcare pro roche also founding member partner fessionals african countries ship prescription assistance programme cambodia see also ensuring access healthcare sponsored pharmaceutical research worldwidepand visit wwwrochehivcom manufacturers america represents countrys leading pharmaceutical research recent move extend access vital biotechnology companiesthe programme offers hivaids treatments worlds neediest areas single point ofaccess public private roche announced january thatas part patient assistance programmes new technology transfer initiativethe company provide local manufacturers within sub similarly genentech provides marketed prod saharan africa least developed countries ucts free charge eligible uninsured patients technical expertise required produce generic treated united states genentech hiv medicinesthis assistance offered free access care foundation genentech conditions attached endowment cystic fibrosisgenentech also member partnership prescription assis threat avian flu pandemic represents tanceto support patient access therapies another critical global health challengeand roche various diseases genentech donated closely involved ensuring vital medicines approximately million dollars independent available neededfollow third party public charities offer copayment ing warnings next global assistance eligible patients influenza pandemic imminent roche ensure worldwide availability influenza drug tamiflu pandemic use business report diagnostics division brief sales millions chf operating profit exceptional items millions chf including charges equity compensation plans number employees key figures change change millions chf chf local currencies sales sales diabetes care centralized diagnostics molecular diagnostics near patient testing applied science ebitda operating profit research development exceptional items diagnostics executive team january severin schwan ceo division roche diagnostics silvia ayyoubi human resources heiner dreismann molecular diagnostics christian hebich finance services tiffany olson north america volker pfahlert centralized diagnostics applied science burkhard piper diabetes care jrgen schwiezer emea europe middle east africa robert yates business development business report diagnostics results sales region roche diagnostics maintained leadership posi tion difficult market divisional sales rose local currencies swiss francs europemiddle east africa us dollars broadly line global market japan growth asiapacific worldwideroche diagnostics launched iberia new products including complete new latin america generation products replace older flagship north america offerings divisions key diabetes management portfolio year division also italic growth rate expanded several new highpotential market segmentssuch dna sequencing operating profit exceptional items decreased local currencies billion swiss francs business areas resulting margin decline percentage points primarily due heavy diabetes care price pressures market startup costs new manufacturing facilities new products roche diabetes carethe market leader diabetes andhigher depreciation chargesthe higher depre management posted sales growth local ciation resulted increase instrument currencies placements business unit launched number ofinnovative products second halfofthese included accuchek compact plus glucose monitoring system builtin test strip drum lancing device accuchek aviva successor accuchek advantage monitor also new market accuchek spirita menu driven insulin pump sets new standards flexibility reliability addition business unit introduced accuchek pocket compass latest software mobile diabetes selfman agement features bolus calculator module enables users calculate bolus insulin requirements basis ofcurrent blood glucose estimated food intake several personal param business report diagnostics top selling product lines sales change product line market segment business area millions chf local currencies accuchek diabetes management diabetes care cobas integra clinical chemistry centralized diagnostics roche hitachi elecsys immunodiagnostics centralized diagnostics amplicor tests clinical molecular molecular diagnostics cobas amplicor diagnostics cobas ampliscreen nucleic acidbased molecular diagnostics blood screening coaguchek coagulation monitoring near patient testing excluding hias homogeneous immunoassays eterswith new generation ofproductsroche term goalplacements ofelecsys e systems diagnostics continues lead way three key advanced yearreaching another record areas effective diabetes management glucose highand thanks strong demand elecsys monitoringinsulin delivery data management probnp assay roche became leading supplier laboratory tests cardiac markers sales growing body evidence documenting elecsys assay helped benefits regular blood glucose monitoring scientific papers published ntprobnp first timea multicentre study verified inclusion marker patient glucose selfmonitoring reduces morbidity management guidelinessee patient story p mortality among people type diabetes findings like expected motivate people global trends mounting pressure health type diabetes monitor glucose care budgetscombined shortage trained closely laboratory staffmean laboratories increas ingly dependent automatedintegrated labora food drug administration fda tory systems offer costefficiency high completed inspection roche diagnostics performancethis creates ideal market environ facility burgdorf switzerland final deci ment rollout cobas new sion whether lift us import alert generation modular analysers mediumsize pumps made facility still pending laboratories centralized diagnostics investments new technologies automate many tasks precede follow actual testing roche centralized diagnostics supplies integrated laboratory beginning pay total solutions clinical laboratories busi expanded cooperation agreement signed ness area reported sales growth local curren german company pvt probenverteiltechnik ciestaking lead first time impor covering preanalytical automation tant segment ofthe diagnostics market strengthened position aleading provider total laboratory solutions rsda new sys growth due primarily continued success tem providing complete preanalytical automation immunodiagnostics portfolio roche already successfully launched nine pursuing leadership immunodiagnostics markets moved step closer achieving medium business report diagnostics new markers point way better care immunodiagnostics represent major share global vitro diagnostics market onefourth last count still climbing roche tapping potential innovative immunodiagnostic markers address unmet medical needs immunodiagnostics exploit basic feature bodys natural defence system disease viruses bacteria foreign substances collectively referred antigens enter body responds producing antibodies bind antigens neu tralise response highly specific data ongoing study assay gross key normally fit one lock antibodies react hadern university hospital munich germany antigens stimulated production encouraging following breast cancer surgery blood test done determine baseline levels immunodiagnostic tests mimic natural defensive tumour marker tests marker reaction explains joachim eberle head research repeated sixweek intervals rise ca development roche centralized diagnostics levels indicate growth new cancer cells specificity antibodies used six twelve months patient develops detect presence particular antigens body symptoms enabling physicians take action sooner hence help diagnosing disease save precious time natural mechanisms antibodyantigen interaction thus giving new hope immunoassay ca example identifies patients health professionals tumour marker protein breast cancer patients early molecular diagnostics company tests hivhcv hepati tis b hbv approved eu us sales growth market share authorities screening livingdonor cadav roche molecular diagnostics remains eric organs tissues well blood plasma clear leader increasingly competitive tissues cadaveric sources including skin market environment blood screening bone ligaments used roughly one mil virology main growth lion medical procedures per year transmit drivers viral infections blood tissues single donor transplanted average five years since roche diagnostics entered insome cases many recipientsthis blood screening marketover million blood highlights significance approvals donations screened using roches hiv towards end year regulatory filing hepatitis c hcv tests roche submitted europe nextgeneration cobas already global leader sector volume blood screening systemwhich expected units testedand became first reach market business report diagnostics core virology portfolio strengthened near patient testing integrated cobas ampliprepcobas taqman system offers laboratories new roche near patient testing reported increase capabilities fully automated sample preparation fullyear saleswith positive growth three dnarna analysis addition three viral core segmentscardiologycoagulation monitoring load tests use platform approved blood gaselectrolytesit leader decen marketing europe tests measure tralised testing testing outside hospital labora amounts ofhivhcv hbv human plasma tory patient selfmonitoring viral load key indicator assessing disease progression treatment response drug resis sales coagulation monitoring products rose tance us regulatory filings three tests especially strong growth recorded planned theunited statesa recent clinical trial shown patient selfmonitoring coaguchek roche diagnostics lineararray hpv genotyping system reduce risk severe complications test received ce mark approval june minor hemorrhages patients commercially available test capable oral anticoagulant therapy reduce identifying high lowrisk genetic variants mortality heart valve replacement human papillomavirus hpv although results support costeffectiveness majority hpv infections clear spontaneously patient selfmonitoring evidence persistent infection highrisk hpv genotypes modern diagnostics help reduce recognised significant risk factor develop costs ofhealthcaresee patient story p ment cervical cancer new roche test expected contribute significantly early market launch ofthe cardiac ntprobnp test identification ofwomen risk cervical cancer outlicensing agreements marker nt probnp expected boost sales cardiol july roche opened worlds largest ogy sectorcardiac ntprobnp used doctors manufacturing facility pcrbased products offices intensive care units rule heart new jersey usa pcr polymerase chain reac failure monitor heart failure patients tion technique produce millions copies virtually dna sequence short placements roche diagnostics blood gas time thus aid detecting infectious agents electrolyte analysers doubled compared genetic variations quickly reliably year last four years roche molecular diagnostics increased kit output new connectivity remote testing devices facility line able continue critical element ofpointofcare testing hospital meet steadily growing demand prod settings roches cobas data management ucts softwarelaunched technological mile stone already worldwide commercial success amplichip cyp test first dna software connects roche nonroche microarraybased test clinical diagnostic pointofcare devices within hospital hospital use received us regulatory clearance january network following approval launch europe three major laboratories united applied science states already added test ser vice offerings test helps guide physicians roche applied science maintained position selecting medicines dosages suitable fiercely competitive marketplace sales rose patients marks major step towards year business area supplies hightech personalised healthcare see patient story systems reagents research laboratories p spurred new product launches sales gathered considerable momentum course business report diagnostics diagnostics help take squeeze healthcare budgets diagnostics help healthcare systems use precious resources efficiently fact addition medical benefits diagnostic tests create economic value although diagnostic tests provide basis twothirds medical decisions account healthcare expenditure many years new technologies regarded cost drivers look ing treatment process whole clear innovative diagnostics help make healthcare deliv treatment started cuttingedge roche ery costeffective also providing sounder diagnostics enable physicians monitor patients basis medical decisionmaking help responses physicians tailor treatment closely theindivid ual needs patients modern tests forexample roche diagnostics leading way researching make easier determine best medicine developing innovative diagnostic tests dosage particular patient result patients change way medicine practiced part receive better treatment less apt suffer committed promoting better understanding serious costly adverse events value diagnostic information among stake holders virology provides excellent examples eco nomic benefits diagnostic products early diagnosis roche diagnostics proactively pursuing effective treatment hepatitis prevent com research document medical plications liver failure liver cancer diag economic value diagnostic information says nostic instruments test kits roche make geoffrey crouse head market development possible detect virus early another governmental affairs context key question roche test used establish viral geno maximise amount health get type treatment novel medicine like money spend pegasys tailored infecting viral strain yearwith business area reporting doubledigit forms marks roches entry attrac increase fourth quarter tive sequencing research market employing awardwinning nanotechnologybased approach genome sequencer lightcycler sequencing system first product two roche applied sciences important emerge strategic alliance formed new offerings genome sequencer roche technologys usbased system enables researchers sequence long dna inventor life sciences roche holds exclusive fragments entire genomes times sales marketing rights life sciences faster commercially available plat sequencing systems life science market business report diagnostics major product launches business area product diabetes care accuchek aviva highend successor advantagesensor blood glucose monitoring system accuchek pocket compass nextgeneration diabetes management software accuchek integra blood glucose monitoring system fully automated test strip handling accuchek compact plus blood glucose monitoring system integrated strip drum lancing device onehand operation accuchek flexlink infusion set centralized diagnostics cobas integra analyser closedtube sampling dedicated hbac glycated hemoglobin analyser basis cobas integra improved reagents prostatespecific antigen myoglobin troponin prolactin forelecsys platforms molecular diagnostics integrated cobas ampliprepcobas taqman instrument hcv hiv hbv first fully automated pcr system assays quantitative detection hiv hepatitis c b cobas ampliprepcobas amplicor hcv qual v qualitative detection hepatitis c virus us ivd cobas ampliprepcobas amplicor hiv monitor test monitoring hiv viral load usivd cobas ampliscreen hcv hbv hiv tests screening organ tissue donations usivd new indication cobas ampliscreen hbv test detecting hepatitis b virus human plasma usivd linear array hcv genotyping test determining hepatitis c genotype ce ivd linear array hpv genotyping test identifies genotypes human papillomavirus ceivd cobas taqman ct test chlamydiace ivd amplichip cyp test microarray drug metabolism testing us ivd lightcycler factor ii v tests factor ii v leiden clotting disorders ce ivd near patient testing cardiac ntprobnp rapid accurate assay quantitative determination ofntprobnp used diagnosis management heart failure patients coaguchek xs handheld system coagulation selfmonitoring omni version software update omni blood gaselectrolyte system cobas new webbased data management solution pointofcare testing inhospitals applied science universal probelibrary set innovative probebased detection system quantitative pcrtests genome seqencer complete platform highthroughput sequencing lightcycler novel platform gene expression mutation analysis lightcycler ivd version lightcycler dna amplification system ce ivd ivd clinical use ce european ce mark certification conformit europenne business report diagnostics lightcycler realtime pcr system chipsa protein chip system impact currently novel platform gene expression mutation undergoing feasibility studies used analysis combining speed exceptional accu initially accelerate clinical testing new racythe new system supports current probe markers mats applications molecular diagnostics research development research activities roche molecular diagnostics focused advancing pcr related research development expenditure totalled technologies enable development new gene nearly million swiss francs approximately based tests taqman amplichip plat salessignificantly divisions forms roche also working new approaches competitors spent molecular diagnostics increasing total throughput pcrbased immunodiagnostics diabetes care businesses analyses testing multiple viral human accounted largest shares ofexpenditure genetic markers simultaneously run diabetes care september roche mayo clinic minnesota usa signed agreement collabo research development efforts business rate developing itenabled drug dose unit aimed making diabetes management selection system use treating psychiatric even simpler example developing software patients information provided system geared special needs offrequent testerswho based patient test data obtained cope huge amounts ofdata amplichip cyp testmayo clinic explore use system wide range psy additionroche working minimally inva chotropic drugsthis area clinical practice sive glucose measuring technologies requiring several drugs often tried minute blood sample sample long treatment cycle time order find one continuous blood glucose monitoring systems best particular patient ultimate aim create artificial pancreas system capable mimicking natural pattern molecular diagnostics also steadily gaining ofinsulin release healthy individuals importance oncologyroches efforts area aimed primarily developing tests early centralized diagnostics cancer detection risk stratificationparticularly solid tumours cancers breast roche centralized diagnostics develops total labo prostate colon leukemia candidate ratory automation systems increase laboratory markers identified currently productivity reducing costs reliable diag evaluated potential use important nostic tests contribute better patient care applications key areas ofinterest include cardiovascular disease cancer rheumatoid arthritis largescale international clinical research pro gramme investigating leukemia classification additionroche stepping research way due completed new biomarkers ofhigh diagnostic value monitor different subtypes leukemia ing disease progression evaluating treatment respond treatments responsebiomarkers used singly incom choosing effective available medication bination sources informationparticularly type oftherapy right outset particu complex diseases like cancer tests multiple lar leukemia subtype particularly important markers often means obtaining acute leukemias progress rapidly conclusive result next generation systems programme compare results obtained measure marker combinations using protein amplichip leukemia tests different laboratories business report diagnostics key product launches scheduled business area product diabetes care accuchek go successor accuchek go meter offering improved feature set anddesign centralized diagnostics cobas series consolidates clinical chemistry immunochemistry testing medium highworkload laboratories modular expandable reconfigurable site configurations using cobas c cobas e modules cobas series consolidates clinical chemistry immunochemistry testing small mediumworkload laboratories links cobas c cobas e psm data manager cobas c clinical chemistry electrolyte analyser extrasmallworkload laboratories standalone system cobas solution laboratory information system supports steps laboratory testing order entry result reporting features connectivity sample management quality control validation capabilities cobas solution central lab data management system wammiddleware instrument interface consolidation providing resultrelated reagent test information molecular diagnostics lightcycler septifast test ce ivd worlds first diagnostic assay detection sepsis causing pathogens directly blood cobas mpv ce ivd multiplex detection test hiv hcv hbv cobas blood screening system cobas taqman hcv v test monitoring hcv viral load applied science genome sequencer system nextgeneration system capability sequence larger genomes lightcycler well including new software modules extension lc allowinguse broader range applications interlaboratory robustness also intended near patient testing confirm data roche gene discovery pro jects prototype test expected ready one mediumterm goal roche near patient research applications end testing develop mobile devices per form urgent medical tests anywhere matter another microarraybased product currently minutes development amplichip p test several research collaborations investigate potential business area plans complete line clinical applications test scheduled new instruments market p gene one ofa family ofgenes called already begun refreshing product portfolio tumour suppressors code proteins pilot launch coaguchek xs coagulation prevent damaged cells reproducing muta monitorthis userfriendly nextgeneration device tions p gene found virtually builtin quality control system capable tumour typesby identifying mutations affect detecting virtually potential source error p function activitythe amplichip p test testingthus making anticoagulant therapy may one day help physicians select anticancer safer ever medicines best suited patientsneeds business report diagnostics applied science roche applied science focuses developing high quality systems reagents use life science research particularly highpotential areas proteomics dna sequencing analysis example business area working broaden research uses ofthe newhighly versa tile lightcycler instrument innovative geno typing products software upgrades introduced products expand applications ofthe genome sequencer also due reach market work way make system even faster access diagnostics amplicare programme one ways roche diagnostics helping improve healthcare delivery hivaids patients parts ofthe world needs greatest subsaharan africa countries designated united nations least developed since inception programme supplying hiv viral load tests sharply reduced prices tests part story sustainability continuity care criticalwe contribut ing fronts well providing expanded training continuing education opportunities doctors nurses supporting efforts monitor health outcomeswe also strive match efforts local needsworking closely laboratories hospitals example determine services types oftechnical assis tance feasible suitable develop targeted solution roche diagnostics plans expand amplicare programme additional countrieswith focus reaching countries listed un lowincome economies preparatory talks already initiated purpose eastern europe latin america additional countries asia business report medication helps osteoporosis take month business report growing older doesnt mean going slower senior sales account manager ginger la motta branchburg new jersey dotes four grandchildren enjoys ride shoulders diagnosis osteo porosis five years ago made realise even simple pleasures like could risk health osteoporosis bone condition common among postmenopausal women people tend think bone hard unchanging fact dynamic living tissue constantly broken rebuiltafter menopause rebuilding slower bone mass decrease making bones weaker likely break ginger eats healthy diet exercises regularlyto keep osteoporosis control takes onceamonth boniva first oncemonthly oral bisphosphonate oral bisphosphonates must taken morning empty stomach patients must stay upright eat least another halfhour hour busy schedule onceamonth boniva ideal solution ginger reduce risk fracture taking one tablet monthand shes much relaxed playing grand children prevention reducing consequences disease helps patients maintain quality life boniva ibandronic acid maintains actually builds bone density reducing risk fracture course patients need stay therapy benefit monthly boniva thats become lot easier patients take tablets year business report board directors executive committee corporate governance board directors corporate executive committee board directors economist international mon etary fund world bank washingtondc annual general meeting february john bell andr hoffmann franz b boards proposals adoptedchairman humer elected additional fouryear terms board franz bhumer continue board ofdirectors director also serving executive capacity rocheand majority seats board current board terms rolf hnggi peter held independent directors brabeckletmathe deanne julius horst teltschik end next annual general meetingon february meeting corporate executive committee board intends nominate mr brabeckletmathe ms julius mr teltschik reelection heino von prondzynski ceo division roche directors terms offour years diagnosticshas decided leave roche year pursue personal interests since joining roche rolf hnggiwho served vicechairman march contributed significantly board since declined stand diagnostics divisions achievementsproviding electionmr hnggi become increasingly active leadership helped division expand private investor pharmaceutical startup global market leadership successfullythe board companiesa situation could potentially give directors would like take additional rise conflicts interests opportunity thank mr prondzynski valu roche decision help ensure con able contribution wish best tinued independence capacities future board ofdirectors corporate executive com mittee extend sincere thanks mr hnggi severin schwan joined corporate executive forhis many years ofdedicated service group committee new ceo division roche diag nostics january schwan yearold addition aforementioned three nominees austrian doctorate law degree reelectionthe board also recommend economics began career roche election beatrice weder di mauro roches thecorporate finance department baselfollow highest governing body yearold native ing several international assignmentshe served baselms weder di maurohas professor head ofglobal finance services diagnos economics university mainz germany tics division put charge since served germanys council divisions regional operations asiapacific economic experts since august prior business report board directors corporate executive committee board directors january leftjohn bell rolf hnggi peter brabeckletmathe brunogehrig andrhoffmann franz b humer lodewijk jr de vink deanne julius walter frey andreasoeri horst teltschik name year birth term endsfirst elected board directors dr franz b humer f chairman prof bruno gehrig c e vicechairman independent lead director rolf hnggi b e vicechairman prof john irving bell c e peter brabeckletmathe e lodewijk jr de vink e walter frey b e andr hoffmann c e dr deanne julius b e dr andreas oeri b e prof horst teltschik e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber finance investment committee presidium board directorsnomination committee b audit corporate governance committee e nonexecutive director c remuneration committee f executive director committee chairperson step february january business report board directors corporate executive committee burkhard gpiper named enlarged effective january eduard holdener peter corporate executive committee appointment hug rolf schlpfer osamu nagayama also became effective january also appointed members roches enlarged yearold german holds degree business corporate executive committeeall four men administration joined boehringermannheim assisting executive management permanent group later acquired roche held participants committee since january several management positions marketing appointed general manager roche diag nostics canada head roche centralized diagnostics mr piper headed roche diabetes care since end mr pipers predecessor staffan ek retired end year board directors thanks mrek significant role strengthening roches diabetes care business contribution success ofthe group whole business report board directors corporate executive committee corporate executive committee december leftjonathan kc knowles pierre jaccoud heino von prondzynski staffan ek william burns eduard holdener franz b humer peterhug erichhunziker rolf schlpfer gottlieb keller osamu nagayama name year birth position corporate executive committee dr franz b humer ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceuticals heino von prondzynski ceo division roche diagnostics prof jonathan kc knowles head global research dr gottlieb keller head corporate services human resources enlarged corporate dr eduard holdener head global pharma development executive committee dr peter hug head pharma partnering staffan ek head business area diabetes care rolf schlpfer head corporate communications osamu nagayama president ceo chugai secretary pierre jaccoud head chairmans office corporate executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa since roche holding ltd principal auditor john morris since group auditors compliance officer dr andreas greuter direct dial number january dr severin schwan january burkhard g piper end business report corporate governance corporate governance roche group meets requirements finance investment committee respect corporate governance complying chairmanrolfhnggi existing legal regulationsthe swx swiss remuneration committee stock exchange directives including com chairmanbruno gehrig mentaries swiss code best practice corporate governance promulgated swiss committees except presidium business federation economiesuisse existing chaired independent directors internal company regulations particular companys articles incorporation bylaws bylaws board directors containing consider principles govern manage details internal structure board ment supervision company including allocation authority responsibilities necessary checks balances order mandates board committees infor ensure good corporate governance mation control mechanisms available board dealings corporate management combine printed annual report key published internet links roche website wwwrochecom enables readers gain snapshot articles ofthe bylaws ofthe reporting date uptodate overview board ofdirectorsthe independent lead director companys key corporate governance information may decision request annual report contains information member convene board meeting without available december ofthe given yearwhile attendance chairman roche board internet provides source permanent meets year assess chairmans perfor constantly updated information companys mancethis meetingwhich held absence articles incorporationthe bylaws cur chairman chaired independent ricula vitae members board direc lead director tors executive committee regularly updated made available internet board ofdirectors periodically conducts self require information assessment ofits performancein selfassess ment focusing number areas including organisational structure board cooperation board executive directors committeewas conducted assistance ofa specialist consulting firm roches board directors organised ensure groups businesses conducted remuneration responsibly focus longterm value creation therefore board directors remuneration members board roche holding ltd delegated certain responsi ofdirectors bilities several committeesas january members board directors committees received remuneration shown table remuneration members board presidium ofthe board ofdirectors directorsfor serving board nomination committee chairmanfranz bhumer httpwwwrochecomhomecompanycomgovhtm audit corporate governance committee httpwwwrochecomhomecompanycomgov chairmandeanne julius comgovbylawshtm business report corporate governance remuneration members board directors additional compensation remuneration committee members chf chf fb humer b gehrig r hnggi j bell p brabeckletmathe ljr de vink w frey ahoffmann da julius oeri h teltschik total per committee membershipyear excluding members presidium vicechairmen chf remuneration paid chairman board fb humer executive member board directors isdeducted agreed salary see remuneration members corporate executive committee remuneration serving independent lead director vicechairman board remuneration serving vicechairman board remuneration additional compensation paid remuneration members corporate nonexecutive members board direc executive committee tors serving aforementioned capacities remuneration committee decides totalled swiss francs previous remuneration members corporate year swiss francs executive committee cash paymentsbonusstock options ssars approving principle nonexecutive members board pension fund benefits board directors directors awarded sharesnonvoting upon proposal remuneration committee equity securities nesstocksettled stock appre decides performance share plan psp ciation rights ssars stock options december held unvested compensation components ssars options awarded previous years psp plan intended align compensation longterm success ofthe company connection acquisition glycart july see finance report note members corporate executive roche group consolidated financial committee received salaries bonuses stock statements changes group organisation optionsstocksettled stock appreciation rights related parties group paid ssars nonvoting equity securities rolf hnggi swiss francs considera shown following tables tion shareholding glycartthis equiva lent pershare basis amounts paid members corporate executive committee shareholders glycart stock additionally receive annual expense allowances swiss francs chief executive officer otherwiseno additional remuneration paid receives annual expense allowance members ofthe board ofdirectors swiss francsin members ofthe corporate executive committee total received expense allowances totalling swiss francs refer stock optionsstocksettled stock appreciation rights ssars business report corporate governance remuneration members corporate executive committee cash payments chf annual salary annual salary annual salary bonus bonus bonus fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total b stock optionsstocksettled stock appreciation rights ssars ssars stock options stock options value chf value chf value chf fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total refer stock optionsstocksettled stock appreciation rights ssars blackscholes valuation described section stock optionsstocksettled stock appreciation rights ssars page richard tlaube stepped corporate three years programme effect executive committee december performance evaluated basis ofmarket left company june richard price dividend yields ie total shareholder tlaube received continuing salarybonus sev returntsr order reduce effect erance payment totalling million swiss francs shortterm market price fluctuation tsr based average market values last three c performance share plan psp months october december members corporate executive commit beginning ofthe programme compared aver tee members ofsenior management whose age ofthe last three months october decem performance major impact roches ability ber ifan investment roche securities achieve corporate objectives indi equal outperforms peer set viduals worldwide participate new psp pro roches tsr increased least gramme established duration programmethe board ofdirectors beginning threeyear period elect increase number nes awarded theprovisions ofthis programme replaced maximum twofold event psp programme number ofnes investment roche securities underperforms reserved participantsthe actual distribution securities depend whether peer set abbott laboratories altana amgen astrazeneca extent investment roche securities shares bayer becton dickinson biogen idec bristolmyers nes outperform average return invest squibb eli lilly glaxosmithkline johnson johnson ment securities issued peer setof com merck novartis pfizer serono sanofiaventis schering panies operating industry ag scheringplough takeda wyeth business report corporate governance performance share plan psp number number nes nes originally targeted targeted psp psp psp value assumption value psp number number value chf value chf fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total value assumption evaluated using yearend price december chf per genussschein nes based number nes originally targeted subject changes allocation value number nes originally targeted plan december spread relevant period time ie year board directors vote actual allocation nes originally targeted december according tsr growth achieved value year psp doubling number nes originally targeted according market value growth achieved spread relevant years total period effective time plan average return delivered peer companies reserved members corporate executive fewer nes awarded committee shown table abovethe board provisions programme nes ofdirectors decide actual distribution roche performance rochetsr peer group average tsrperformance total shareholder return tsr value chf invested roche market capitalisation billions chf roche securities chf nonvoting equity security nes share prices translated constant chf exchange rates tsr stock price plus dividend business report corporate governance nes cash equivalent plan close indirect benefits ofthe reporting year employer contributions made social security schemes pension plans last years roche securities shares groupwide employee stock purchase plan roche nes including dividend yields outper connect respect members corporate formed average return delivered peer executive committee shown table pharmaceuticals diagnostics companies indirect benefits roche ranked second end psp pro roche connecta voluntary stock purchase gramme time market planemployees opportunity buy roche value roche increased billion swiss nonvoting equity securities nes francs billion swiss francs equivalent amount equal annual salary growth billion swiss francsthe dis discountnes purchased plan tribution dividends totalled billion swiss subject holding periodwhich switzerland francs four years current psp programme e remuneration emoluments loans based moving threemonth average corporate officers constant exchange rates roche one year gottlieb keller taken mortgage loan ranked number one compared peer set swiss francs pension fund companies operating industry fhoffmannla roche ltd interest rate pa interest rate loan fixed roches market value increased billion december swiss francs per billion swiss francsequivalent growth billion pension obligations seven former members swiss francs per distribution corporate executive committee widows dividends totalled billion swiss transferred pension fund francs onetime payment swiss francs made fund cover resulting addi average total shareholder return tsr tionalliabilitiespensions totalling swiss ofthe peer set constant exchange rates sig francswere paid totwo former corporate executive nificantly lower thus tsr roches committee members securities points higher average tsr peer companies constant otherwise additional remuneration paid exchange rates current former members ofthe corporate execu tive committee indirect benefits pension fundsmgb ahvivalv roche connect chf chf chf fb humer wm burns e hunziker ga keller jkc knowles h von prondzynski total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits business report corporate governance f highest total remuneration stock optionsstocksettled stock appreciation chairman board directors ceo rights ssars franz bhumer member ofthe board member ofthe corporate executive committee december members corpo highest total remuneration please rate executive committee held optionsssars refer remuneration ofthe members ofthe cor january shown table porate executive committee subject changes page allocation computations relating threeyear performanceshare plan psp salary follows highest total remuneration chf cash payments stock optionsssars value based blackscholes formulaminus performance share plan pension fundsmgb roche connect total value blackscholes valuation described section stock optionsstocksettled stock appreciation rights ssars refer remuneration members corporate executive committee c performance share plan psp paid mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits payments pension schemes shareholdings options shown table issued roche employee stock options option directors andr hoffmann andreas oeri entitles holder purchase one roche non members founders family voting equity security nesgenussschein closely associated belong share holder group pooled voting rightsat end terms well established option group held shares planthe strike price options shown issued shares andr hoffmann serves closing price roche nes trading day spokesman shareholder group detailed prior roche annual media conferenceall information group found options shown nontradableonethird finance report note roche group options subject vesting period one consolidated financial statements related par yearonethird vesting period two years ties notes financial onethird vesting period three years statements roche holding ltd unvested options lapse without compensation addition december nonexecu member voluntarily leaves company tive members ofthe board ofdirectors persons vested options must exercised within limited closely associated held shares period oftimeifthey tradablethe fair value members corporate executive commit options would calculated date tee persons closely associated held issue based blackscholes formula shares date deducting average twoyear vesting period business report corporate governance stock optionsssars number stock optionsssars held december members executive committee total number strike price chf expiry date allotment value per stock option ssar chf value based blackscholes formula minus ssars ssars shown table issued relationship group auditors statutory roche january basis ofthe roche auditors longtermprogram instead stock options ssar right benefit financially annual general meeting roche holding increase value nonvoting equity security ltd february kpmg klynveld peat nesgenussschein grant date marwick goerdeler sa kpmg elected exercise datethe strike price ssars group auditors statutory auditors informa terms perennial plan closing tion appointment ofthe group auditors price roche nes trading day date principal auditor took roche annual media conference third office provided group auditors anniversary ofthe grant dateall remaining ssars statutory auditors participate audit shall vestedonethird ofthe ssars subject corporate governance committee meetings vesting period one year onethird auditors make written oral reports vesting period oftwo yearsand onethird vesting results audits audit corporate period three yearsvested ssars must exer governance committee oversees assesses cised within seven years grant date ie auditors makes recommendations board exchange ofssars gain nes unexercised information responsibilities ssars lapse without compensation audit corporate governance committee see tradablethe fair value ofthe ssars would cal article bylaws group auditors culated date issue based black statutory auditors participated three meet scholes formula deducting ings audit corporate governance average twoyear vesting period committee strike priceexpiry date allotment price reports ofthe group statutory auditors shown tablethe value options set forth pages respectively ssars table remuneration ofmembers finance report ofthis annual report corporate executive committee b stock optionsstocksettled stock appreciation rights kpmg received following remuneration ssarson based calculation services group auditors statutory method used time ofissue auditors roche holding ltd roche financial companies httpwwwrochecomhomecompanycomgov comgovbylawshtm business report corporate governance millions chf capital structure auditing services information roches capital structure auditrelated services provided finance report notes tax consultancy services financial statements roche holding ltd total additional details contained articles ofincorporation ofroche holding ltd group auditors statutory auditors changes equity detailed finance elected year annual general meeting report notes financial statements ernst young ltd received following remuner roche holding ltd ation services auditors ofgenentech company share capital chugai swiss francs divided fully paid bearer shares nominal value swiss franc millions chf eachthere limitations transfer genentech chugai audits shares cap voting rights upon consulting services provided depositshares voted without restric genentech chugai tions total authorised conditional capital addition nonvoting equity secu additional information relating corporate rities nes issued bearer formthey governance form part ofthe share capital confer voting rightseach nes confers rights group structure shareholders one share participate available earnings roches operating business organised two liquidation proceeds following repayment divisionspharmaceuticals diagnostics share capitalroches nes rights per pharmaceuticals division comprises taining thereto inclthe provisions securing three business segments roche pharmaceuticals claims described articles genentech chugai incorporation ofroche holding ltd diagnostics division consists offive business information debt instruments areas diabetes care near patient testing cen issued outstanding bonds provided tralized diagnostics molecular diagnostics finance report note roche applied sciencebusiness activities carried group consolidated financial statements debt group subsidiaries associated com panies significant subsidiaries associated additional information employee stock companies listed finance reportnote options provided finance reportnote roche group consolidated financial roche group consolidated financial state statements subsidiaries associated compa ments employee stock options equity niespages compensation benefits major shareholders listed finance roche issued options apart reportnotes roche group con awarded employees issued solidated financial statements equity attribut connection debt instruments able roche shareholders related parties neither options awarded employees pages notes financial debt instruments issued statements ofroche holding ltd effect roches share capital andr hoffmann andreas oeri serve board ofdirectors representatives ofthe share holders pooled voting rights receive remuneration mentioned remuneration members board directors relationships exist shareholders httpwwwrochecomhomecompanycomgov pooled voting rights comgovartihtm crossshareholdings business report corporate governance board directors corporate executive finance investment committeethree committee meetings information member board remuneration committeetwo meetings directors including years management contracts fall elected years terms end within meaning ofsubsection ofthe swx corporate executive committee listed directive information relating corporate pages curricula vitae infor governance mation board executive committee members including information board mem participatory rights shareholders berships available internet participatory rights shareholders none ofthe nonexecutive members ofthe board defined roches articles ofincorporationas ofdirectors member ofthe corporate roche shares issued bearer executive committee roche restrictions admission annual general group subsidiaries three financial meetingswith exception shares must years preceding current reporting period deposited within specified period date internal organisation board direc meeting admittance card must tors division ofauthority responsibil issued shareholders name provided ities board management articles incorporation share governed bylaws holder elect represented another board directors established system shareholder annual general meeting controls overseen audit articles incorporation contain restrictions corporate governance committee consists exercise ofvoting rightsand quo ofthe following elements rum requirements stipulated reports financial operating risks articles incorporation internal audits shareholders representing shares nominal compliance officer value ofat least million swiss francs request safety health environmental protection placement items agenda department annual general meeting must done corporate sustainability committee later days date ofthe meeting scientific ethics advisory group seag issues relating genetics genetic engi change control defensive measures neering established articles incorporation contain provi year several blackout periods imposed sions mandatory bid rule swiss law senior employees prohibited applies trading company stock following changeofcontrol clauses blackout periods effect components remuneration based roche january february nes would terminated event ofan acqui april april sition vesting period restrictions pre july july existing awards would removedso october october options could immediately exercised blackout periods changed chair man board directors circumstances warrant board directors held total five meet ings board committees met fol httpwwwrochecomhomecompany lows comgovhtm presidium board directors httpwwwrochecomhomecompany nomination committeefive meetings comgovcomgovbylawshtm audit corporate governance commit httpwwwrochecomhomecompany teefour meetings comgovcomgovartihtm business report corporate governance information policy compliance officer provided articles incorpora tion corporate notices published compliance officer committed ensuring swiss official gazette commerce schwei roche corporate principles consistently zerisches handelsamtsblatt daily complied throughout roche group newspapers designated board directors also serves contact person shareholders basler zeitung finanz und wirtschaft lagefi employees customers suppliers general letempsneue zrcher zeitung public issues relating implementation compliance principles employees roche reports halfyear fullyear results parties become aware violations business reports published print online ofroche corporate principles bring formats media events addition first attention oftheir managers supervisors report thirdquarter sales figures published compliance officer andreas greuter year april octobercurrent dates ofpubli direct phone number cations available english german disclosures treated confidentialemploy internet ees make disclosures penalised relevant information documentsinclud company sobut immune ing media releases presentations prosecution legal violations com analyst investor conferences avail pliance officer submits regular reports audit able english german internet corporate governance committee publications ordered email fax telephone baselwebmasterrochecom tel fax contact address investor relations f hoffmannla roche ltd investor relations corporate finance basel switzerland tel fax additional informationincluding details spe cific contact personsis available internet nonapplicabilitynegative disclosure expressly noted information contained mentioned herein nonapplicable omission construed negative declaration according requirements swx corporate governance directive including commentary httpwwwrochecomhomecompany comgovcomgovartihtm httpwwwrochecomhomemediamedeventshtm httpwwwrochecomhomeinvestorsinvcontacthtm business report responsible sustainable management responsible sustainable management sustainability integrated indexes djsi world dow jones stoxx approach sustainability indexes djsi stoxx improved position roche also met roche strives create sustainable value ftsegood criteria thus remains member major stakeholderseconomicsocial environ ftsegood index seriesthis clear sign mental progress interdependent influence recognition ofour efforts area companies create economic value resources make active commit ment society environmentat networked structures firm footing time business success feasible without intact environment society embraces corporate sustainability committee csc achievement innovation established corporate sustai nability charter adopted roches corporate sustainability hallmark roches core busi executive committee board directors nessafter allour corporate strategy research charter describes mission context based corporation nature longterm composition procedures ofthe corporate sus given research development cycles often tainability committee committee drafts last decadeswe accept associated risks order coordinates strategy sustainable develop develop innovative diagnostic products ment reports efforts progress medicines help save lives least alleviate area also responsible developing sufferingthis see important amending corporate guidelines corporate contribution societyin roche selected sustainability committee authorised appoint inclusion dow jones sustainability world crossdivisionalcrossfunctional expert groups develop review position statements rules information charter found wwwrochecomensustcommcharterpdf corporate sustainability committee reports directly chairman ceo submits regular reports board ofdirectorsaudit corporate governance committee networked structure ability rely required expertise line functional managers ensures firmly embedded organisation enjoys support senior management thus promoting integration sustainable develop ment group operations march roches corporate executive committee appointed csc core team pierre jaccoudchairsecretary corporate executive committee head ofthe chair mans office peter bierihead ofcorporate audit business report responsible sustainable management andreas greutercompliance officer erwin schneiderhead ofcorporate finance peter heerhead ofpublic affairs accounting controlling gottlieb kellerhead ofcorporate services peter schnurrenbergerhead ofcorporate safety human resources health environmental protection horst kramerdelegate ofthe diagnostics dianne youngsecretarycorporate finance division investor relations karl mahlerhead ofcorporate finance investor relations bruno maierhead ofcorporate law patents deal risks christopher murraydelegate ofthe pharmaceu ticals division part ofthe business planthe material risks rolfschlpferhead ofcorporate communica achieving companys goals identified tions assessed group risk management team innovation mindset promotes sustainability roche working number years professor ulrich steger director forum corporate sustainability management imd lausanne switzerland professor steger prompted imd roche start working together forum corporate sustainability management roche member thoroughly analysed link companys core strategy sustainability roche management wanted bet ter understand companyspecific drivers behind sustainable development one key finding roche safety health environmental protection risk already closely tied business model sustain management research corporate culture ability generally roche benefit cooperation first history roche familyowned firm imd plays important role tradition commitment demands made researchbased health roche pledged demonstrab care companies steadily increasing issues ly present since company founded cost explosion healthcare access medicines much alive roche today secondly roche stands transparency clinical trials examples competitors account level innova changing dynamics healthcare sector tion sharp focus developing novel approaches cooperation hope show business automatically results sustainable business practices model brought even closely line thirdly management professional thorough demands business sustainability particularly way links business model sustainability areas abundant examples roche seeks innovative simply pragmatic solutions information imd wwwimdch business report responsible sustainable management date total trials registered beat widler head global clinical quality assurance roche roche began making information clinical trials available publicly come debate surrounding clinical trial transparency prompted roche create desired open communi cation quickly unbureaucratically wanted reinforce confidence public patients clinical trials evaluated various internal options decided build registry managed independent company centerwatch roche present ie end feedback inside roche outside studies entered registry positive visitors week two thirds ongoing completed autumn expect private users instance patients include studies would like find clinical trials results studies registered ongoing trials phase ii received initial regu experience project latory approval october roche lead im pleasantly surprised ive never seen project manages moreover completed studies registe implemented quickly efficiently registry red regardless whether outcome made public important patients public large also supports number efforts undertaken feedback received project roche ensure colleagues various teams internet site registered trials countries faster clearer overview accessed clinical trials corporate sustainability committee ciated factors define roche position involved risk assessment processes regard values responsible assessing see socialenviron mental ethical risks identifies roche complies ethical standards roche confident institutionalisation sustainable core ethical values throughout com roche employees committed comply pany necessary precondition effective ing relevant localnational internation approach al laws roches guidelines often go beyond legislation standards coming year key areas sustainable based roche corporate principles development defined relate pri together roche directivesguidelines marily animal experimentationsclinical studies regulations comprise roche code ofcon new technologies nanotechnology ductas ofa specially developedinteractive roche undertakes continually evaluate asso computerbased learning program covering business report responsible sustainable management standards deployed worldwide every hier prompted two objectives one thing archical levelsince issue ofcrucial impor information meant help patients consulta tance vital ensure roche tion physicians find clinical trials employees actively participate programme participatefor anotherpractising roche companies united stateswhich physicians healthcare professionals compliance programmes exempted able obtain balanced overview clinical programmefor information trial results information found code conduct please go httpwwwrochecom wwwrochetrialscom enhomecompanycomgovcomgovcondhtm find roche corporate principles ethical responsibility research internet wwwrochecomenhomecompanycom development govcomgovcondcomgovprinchtm daytoday work developing new medi corporate sustainability report also addresses cines diagnostic testsethical issues often arise societal issues context enforcement roche therefore taken clear position policies procedures addressing fraud research human subjects brought briberycorruption tracked reported cases attention employeesfurther information violations followed necessary mea found wwwrochecompagesdownloadssustain sures taken pdfposhumsubrespdf global ethics liaison office established research activities roche meet drive systematic resolution rigorous ethical standards issues open roche employees queries submitted issues ranging innovation key success business trial plan design data protection compensa endeavours research implies responsibility tion patients clinical trials problem groundbreaking science inevitably entails satisfactorily solved together risks well opportunities set high liaison officethe case referred internal ethical standards research activitiesroche bodywhere necessaryan external advisory group issued clear directives governing ethical may consultedfurther information roche considerations observed genetic research framework discussing resolving ethical issues clinical trialsanimal experimentsetcwe thereby human subject research wwwrochecomsust provide scientists decisionmaking tools resethissclintpdf backed targeted continuous training eventsroche first company industry back thesto set external ethics body responsible animal experiments advises supports internal research depart ments roche researchbased healthcare compa niesthe appropriate responsible use ofanimal experiments essential part biomedical clinical trial protocol registry researchand majority ofsuch experiments clinical trial results database therefore prescribed authoritiesfor past three years roche gathering data glob believe roche ethical obligation al research within companythe aim dis ensure scientifically clinically relevant data cuss type scale projects clinical trials made available research managers andtogether themto seek publicin early roche first company ways optimise use animals research industry set clinical trial protocol reg without jeopardising quality ofthe work istry independent host idea safety ofpatients business report responsible sustainable management past year datainclude figures biodiversity bioprospecting research sites also contractual partners animals used roche recognises issue biodiversity experiments rats mice retention traditional skills growing nonhuman primatesroche simply importanceparticularly lowincome countries source difficult experiments con roche supports principles un conven ducts within company thus taking full tion biological diversity ofroches global responsibility themwith aid innovative position global roche statement biodiversity technologies biomarkers company found wwwrochecompagesdownloads endeavouring reduce number sustainpdfroposbiodivpdf experimental animals usedthis also costeffec tive approach nanotechnology take publics concern use ani mals scientific research seriously roche roche tracks new technologies closely assess endeavours set highest ethical standards whether help improve productsser thusby end ofall roche research centres vices processesnanotechnology one new accredited aaalac association technologywe studying ethical social assessment accreditation laboratory implications ofthis form ofminiaturisation well animal care international largest roche potential practical applications expert research centres already certified group within corporate sustainability com futurefurthermoreall contracts third parties mittee roche currently drafting position include clause stipulating aaalac paper nanotechnology due com requirements must met roche reserves pleted early right conduct audits verify care use ofanimals within roche group stem cell research intensively coordinated futureas first steproche appointed one person organ roche generally interested relevant scientific ise groups training activities areathese developmentsfor instance stem cell research efforts backed global networkfur applications currently however roche ther information found wwwrochecom engaged activities area therapy homesustainabilitysusressusresanimhtm using replacement tissue stem cellsnor employ methods technologiesmore roche decided engage human genetics bioethics cloning reproductive purposes thes roche assisted recognised inter roche developed clear position stem cell national experts drew roche charter research related applications cloning geneticsand since working together found wwwrochecomsustposstem independent bodythe science ethics advi cellspdf sory group seag regular meetings held seag advises roche matters relating charter particular genetics general marketing exampleseag addressed issues relat ing ethicsbiomarkers genomicsformulated roche established implemented number recommendations issues reviewed ofinternational guidelines design use corresponding position papers submitted advertising material websites struc rochefurther information seag found turing events globally applicable rules wwwrochecomensciethcharthtm ensure use ofadvertising material complies business report responsible sustainable management legally valid regulations roche regularly reviews quality standards information see wwwrochecomensusethguidel systems constantly develops themthis review prompdf however roche goes development task ranges conducting legal provisions instance recognised internal audits systematically monitoring pro pharmaceutical research manufacturers duct quality analysing trends promptly res ofamerica guidelines directtoconsumer ad ponding complaints customers vertising guidelines come force roche reinforced trai ning programmesmoreoverwe implemented protection counterfeits european marketing code european federation pharmaceutical industriesassocia counterfeit pharmaceutical diagnostic pro tions efpia within roche purpose ducts violate property rights also jeo drafted number internal guidelines pardise health patients undermine general managers roche companies confidence health system roche combats responsible implementing infor forgeries rigorouslyin roche established mation see wwwrochecomenhomesustainability global policy outlining measures place susethsusethmarkhtm prevent counterfeitsin addition technical mea sures relating design labelling packaging focus primarily monitoring market ensuring product safety agreeing business partners clearly defined arrangements audits forgeries roche products must effective discoveredroche immediately informs autho allthey must safeat roche large number rities ifappropriate also general public people work area drug safetywhere seek protect patients adverse drug reac tions identifying effects early possible classifying terms severity important many undesi rable effects headache example may harmless comparison disease treated ega lifethreatening condition cancerin casethe benefits ofevery medi cine must weighed risks involved employees working area drug safety systematically monitor roche products around worldeven registeredin staff reviewed assessed total reports ofadverse drug reactionsonce undesi rable effect identified product information supplemented accordingly conjunction responsible authorities roche committed comprehensive quality management system ensures qualitysafety efficacy medicines diagnostic tests roche standards based specifications laid recognised international bodies healthcare authoritieseach every employee responsible ensuring guidelines fully complied area moreover business report suddenly realised life hanging thread business report tale lifesaving diagnosis heart failure mohinder pratap johar easy man admire eats healthily makes sure gets enough physical activity still leads busy life things might turned quite differently started feeling tired short breath instead usual fit self doctor diagnosed high cholesterol put medication didnt seem help fortunately happening time elecsys probnp cardiac test launched mohinders native india test done renowned delhi heart lung institute results showed alarming rise blood levels protein produced heart indicating mohinder suffering heart failure condition heart muscle longer pumping efficiently examinations revealed mohinders life hanging threadthree arteries supplying blood heart clogged putting risk massive heart attack immediately underwent bypass surgery meantime mohinder resumed virtually normal activities prefers dwell might happened without heart test diagnosis getting fast accurate diagnosis matter life death within minutes elecsys probnp determine whether person shortness breath heart failure even early stages disease conventional tests fail thus help prevent disease promote earlier treatment sometimes help save lives business report dialogue stakeholders listening learning analysts discuss performance gain stakeholders feedback expectationsroche con tinue ensure market players receive regu term stakeholder refers individual lar updates business strategy business group individuals influence performance roche committed transparent interest companys ability achieve fair reporting available simultaneously objectives include particular market playersas outlined communi employees patients medical scientific cation policyfurther information found personnelinvestorsthe authoritiessuppliers wwwrochecomcommunicpolepdf feedback mediaour relationships stakeholders performance importantand rea based general commitments set son participate number investorrela corporate principles also geared specifi tionstargeted external surveys including cally concrete needs ofboth sides thomson extel institutional investor research group surveysas well additional surveys customers website annual report thomson extel survey roche investor rela roche strives excel every areaincluding tions team pharmaceuticals division customer relations happy receive awarded first place ahead competitors positive feedback customersin particular information investor relations found patients medical specialistsbut regard even wwwrochecomenhomeinvestorshtm complaints important source information possible improvements aim respond employees employee organisations quickly needs ofour customers develop sustainable relationships communicate roche believes business depends patients benefit products talent performance dedicated employees services following channels crucial factor success therefore recruiting healthcare professionals pass patients motivating developing retaining outstanding views us productrelated websites people make every effort promote open wwwaccuchekcom wwwbonepaincom twoway communication company patient organisations foster cooperation crossdivisional cross border teams key elements human holders shares nonvoting equity resource management set roche securities investors employment policy information wwwrochecomenhomesustainabilitysussocsus interest cultivate close trans soccommcomgovemphtm parent relations shareholders holders shares nonvoting equity securities finan roche employment policy statesamong cial analysts help decide future focus thingsthat right every employee roche expect kept datewe engage part employee organisation roche ongoing frequent substantive dialogue ready work together open dialogue legal shareholders numerous channels employee representatives countries management roadshows broker confer operates major ences visits roche teleconferences roche restructuring reduction personnel organised events topics key interestduring management met investors business report dialogue stakeholders important stakeholders significance roche employees approximately sales revenue used roche compensation employees billion swiss francs salaries roche provides employees countries attractive jobs holders shares trust holders shares nonvoting equity securities roches strategy nonvoting equity securities management important success billion swiss francs profits paid form dividends profits invested longterm increase company 's value patients medical products sold countries instrumental improving quality scientific community life often prolonging life last year invested billion swiss francs professional associations research development new products services patients participating clinical trials benefit latest drug developments public sector roche paid taxes amounting million swiss francs thus makes considerable contribution financing state infrastructure programmes addition relationship oftrust cooper continue develop provide effi ation management employee repre cient solutions health problems safeguarding sentatives local level roche europe environment receptive research forum employee representatives open innovationwe therefore consider different countries meet members roche important engage dialogue political de management proved sound basisthe cisionmakers legislators regional roche europe forum represents approximately national level also seek contacts employeesieabout ofthe workforce counterparts european interna roche keep records employeesmem tional stage direct contacts go hand hand bership oftrade unions degree ofunion efforts within industry organisations isation individual affiliates according local estimatesabout quarter ofroche employ society nongovernmental organisations ees members ofa trade union slightly interest groups represented form employee organisation roche cultivates longterm cooperative relation ships nongovernmental organisations authorities public sector ngos group plays active role partnerships primarily contributing human roche strives maintain relationships resources knowhow lesser extent relevant health authorities players public fundingthe following selection sector long term strategically driven full list organisations initiatives transparent active political legal roche works involved environment highly complex governed international regulatory intricaciesour goal national international business industry involved early stage political associations processes relevant businessso world business council sustainable develop intervene proactivelywe present posi ment wbcsdroche founding member tions transparently primary aim ensure wbcsd involved various working business report dialogue stakeholders groups within organisation suppliers business partners business charter sustainable development icc international chamber commerce manufacturers specific intermediates roche endorsed charter founding signa products whose development roche involved tory already committed observing roche stan responsible careroche regards responsible care dardsthey also covered compliance pro important aspect ofsustainable development cedures monitored observance ofthese dedicated putting practice regulationswe keep particularly close watch world environment center wec roche suppliers approach workplace safety active member since earlys occupational hygienepollution waste manage global environmental management initiative mentin waywe aim ensure sup gemi pliers service providers follow legal global business coalition hivaids requirements also principles ofsustainabil pharmaccess foundationcareprogramm ityroche recently released set ofguidelines gov european coalition ofpositive people ecpp erning relationships suppliers service development disaster relief organisations providersthese guidelines set formal terms international committee red ethical requirements companies cross national associations purchase products services find information subject wwwrochecom extended list main stakeholder contacts ensusethguidelsuppdf organisations roche member found internet wwwrochecomen homesustainabilitysussocsussoccoopsussoc coopinthtm business report dialogue stakeholders reporting viewed stakeholders sustainability reports focused verdict follows overall panel felt information requirements stakeholders roche carried substantial detailed important take feedback commendable piece work sustainability account improving finetuning report report demonstrates roches real commit reports ment sustainability gives evidence clear obli gation comply gri standards provides roche sustainability report received num many examples case studies good work ber awards even nominated carried members company many parts european sustainability reporting award world detailed examination report award ceremony scheduled february yielded recommendations improvements sub fact successfully completed assessment sequent reports included integration risk process renewed inclusion dow jones management detailed objectives performance sustainability indexes also ascribed part figures greater transparency crossreferencing report improving certain aspects report sustainability roche business model take due account feedback stake descriptions conduct towards stakeholder groups holders detailed evaluation made panel improved readabilitystructure featuring wide range expertise made utmost implement improvements representatives ngos investors together confident present report comes even experts fields communication governan closer meeting stakeholders information requi ce corporate social responsibility auditing rements business report feeling regained control disease gave huge psychological lift business report herceptin breakthrough women herpositive breast cancer maggie duke specialist hygienic engineering vevey switzerland diagnosed breast cancer small hard painful lump found breastafter removal lump maggie began treatment chemotherapy radio therapy hormonal therapy unfortunately within year cancer spread bones liver tests showed maggie herpositive breast cancer aggressive type requiring special care treated combination chemotherapy herceptin drug designed specifically herpositive cancer within months beginning treatment herceptin maggies outlook improved dramatically giving huge psychological lift renewed hope leading full active life since starting treatment herceptin seven years ago maggie carried normal continuing work travel participate muchloved sports thanks health energy regained even able participate longdistance cycling events help raise funds cancer research therapy breast cancers overproduction protein results fastgrowing tumours respond poorly chemotherapy alone herceptin trastuzumab specifically targets shrinking tumours without harming healthy cells advanced early disease herceptin improves survival maintaining quality life women herpositive breast cancer business report commitment employees successful business eastern european regionleading creates new jobs crease headcount overall increase number new positions grea recent yearsroche expanding faster test research development market competitorsthis led increase ing sales roche group hired total headcount many business areas regionsin new employees order fill vacan roche group created total new cies well create new jobsbesides retaining number employees personnel costs division change personnel costs change roche group pharmaceuticals diagnostics others million francs number employees region change europe switzerland alone north america latin america asia japan alone africa australia oceania jobsan increase headcount increased talented motivated employeesit also impor diagnostics division tant view goal increasing sales pharmaceuticals divisionofwhich genentech profit take effective approach attract accounted forin roche spent mil ing new talent httpcareersrochecom lion swiss francs employee remuneration increase million swiss francs previous yearthese figures exclude impact employment policy ofa oneoffgain return ofpart ofthe chugai employees pension fund japanese govern employment policy lays require ment ments human resources management roche group meet also establishes largest number ofnew positions created rights obligations roche employees regions europe north america regard company information sales also grew faster average topic available wwwrochecomenhome instance saw founding ofnew companies companycomgovcomgovemphtm business report commitment employees roche popular employer climber popularity employer europe record employee satisfaction conducting labour market highly qualified talents surveys two indirect indicatorsillness pharmaceutical industry extremely competitive rate departures initiated rochea glob since roche considerably improved al illness rate clear indication global presence market becoming employees enjoy good working conditions feel effective attracting outstanding employees comfortable working roche approach twopronged employer total attrition rate ofpermanent staffwas branding underscores key advantages number regretted losses roche global employer industryand employeesthe proportion ofdepar introduction global erecruiting tures qualified staff highest sales launched internetbased global recruitment administration pleased tool enables candidates view current lowest numbers departures qualified staff vacant positions glanceapply job online research production register global various local talent marketing poolsthe tool used candidates register apply employment demonstrates overall roche count past year roche achieved three demonstrable stable pool motivated employees risk competitive advantages recruiting become achieving projected results business faster efficienta better selection critical areas result significant numbers growing number well qualified external appli regretted losses still regarded minimal fluctuation employees regretted losses ie fluctuation initiated roche employees cants possibleandlastlytransparency inter performance culture roche nal applicantsroche come considerably closer achieving goal one door roche since performance management em unique combination systems phasised key management instrument gen end ofall known vacancies worldwide erating sustainable added value rochethe link viewable websitethis percentage corporate goals daytoday busi increased ness carried management employees forged using goalsetting managementin pro roche companies num cessthe performance ofmanagement staffis mea ber ofprizes topped rankings attractive sured terms contribution sustainable employeregroche genentech usain value creation within companyall senior man germany best employer switzerland best agers roche share common goal sustainably employer women spain best employer increasing enterprise value measured australiaroche also voted highest opac operating profit cost ofcapital business report commitment employees one door roche roche vacancies glance beginning roche launched global personal data cv registered career internet site httpcareersrochecom roche talent pool soon vacancy comes shows vacancies within group glance roche contacts potential candidates whose date countries linked site profile matches requirements job ques meant end tion roche employees also apply job openings vacancies roche could viewed online site way roches career internet site unique contains information roche individual instrument industry supports groups country affiliates well vacant positions growthdriven corporate strategy anyone interested applying job roche target group standardised per regular feedback development reviews formance managementwhich originally cornerstones performance management senior management approx managerswas career development staff promoted higher extended include larger population specific management positions basis oftheir leader critical segmentsin roche refined ship qualities actual performance groupwide standardised database integrat ed system provides goalsetting agreements succession management process global greater transparencythus facilitating compar key positions well established reviewed ison controlit also provides broader factual regular intervals succession planning carried basis decisions regarding developmentpromo every yearfor groups tions transfers top managers group divisional level talent situation roche encouraging affiliates various goalsetting whole group average models performance management regular succession candidates key position com feedback performance placealtogether pared bestprac workforce defined goals set tice range candidates per positionwe objectives regularly receive feedback confident focus performance mana performance gement produces sufficient number internal candidates ensures high standardthe risk ofgaps key positions talent management development causing negative impact business result roche people leaving therefore negligiblein cases ofvacancies among top business success rochetoday future positions filled within short time depends efforts large number moti processes global succession planning vated highly qualified employees man talent identification taken agers characterises performance culture adapted many countriesin ofroche roche high degree ofindividual responsibility affiliates systematic succession planning training management development total hours invested trainingstaff development million million training time per employee days hours days hours business report commitment employees process place affiliates put roche introduced leadership charter programmes place systematic identifi competence model managers company cation development oftalents adapted divisionsthis model based essential competencies man employee development roche takes many forms agers roche possess gives roche primary tool process development managers consistent view expected planin training development plan terms ofmanagement competencies described concrete development prospects steps another achievement new execu agreed roche employees tive development programme senior manage addition continuing educationthe plan calls ment roche begin target strategic postings oftalented employees abroad group programme top managers growing number project assignments job company rotation effort deal efficiently peaks compensation benefits work volume employed employees temporary basis per end compared remuneration policy adopted per endin additionwe cur designed support value creation reinforce rently training apprentices offering roches culture performance innovation prospect ofa career future delivering remuneration meet employees roche employees already participating roche connect lisa teverson group head compensation benefits exactly roche connect programme function roche connect share purchase programme gives roche employees option acquire roche nonvoting equity securities known genussscheine switzerland discount thus chan ce participate companys growth pro gramme started offered employ ees countries worldwide great success given short time span since programme next steps roche connect launched implemented programme countries relatively easy cur participate programme rently offer plan countries like usa china soon roche connect launched country legal requirements much complicated permanent employees participate world continue check feasibility especially wide percent employees china hope soon able include offered already decided take part pro employees countries roche connect gramme however developed temporary achieve goal still lot work employees since shares generally considered longterm investment business report commitment employees needs futurethe first awards including changes pension plan made roche long termthe new incen employees switzerland tive programme executives key managers approved end ofparticipants receive either stocksettled stock appreciation promoting diversity workplace rights options acquire genussscheinedepen ding depending tax efficiency marks roche places high value diversity seeks notable change particularly usa benefit integrating differences per incentives traditionally based american spective groups activitiesroche employs depositary receipts instead genussscheine people countries affili incentives entitled participants worldwide ates headed general managers local based growth value country trend risingthe affiliatesman genussscheine thus everyone involved agement teamstooboast consistently high pro immediate financial interest increasing com portion staff local regiontalent pools panys value worldwide feature growing percentage ofperson nel variety ofcountries continentsthe following two awards employees corporate center come roche connectthe employee stock genussschei countries ne purchase planroche received exter nal recognition employee equity pro roche aims attractive employer grammesthe global equity organization geo women men reason promotes leading international organisation promoting diversity staff fourth year share ownership employees awarded roche row roche recruited women award creative innova menwomen account entire work tive design companies force contrast employeesthis time award received employees left roche women new roche long term incentive programme managers roche femaleamong making award judges praised way identified global key positions mainly global roche identified addressed differences senior middle management ofall incum prior incentive plansand changing compet bents female itiveaccounting tax environmentsto arrive new global programmewith launch ofthe respect worklife balance also key con plan argentina country cern rochethis follows different paths depend included roche connect bringing total ing country based straightfor number countries plan offered ward principle instance roche supports membership plan also continued grow employees enable deliver optimal per significantly reaching vs formance accordance family obliga indication roche tionsthere variety ofworking arrangements employees identify company roche special workingtime eg parttime employment flexitime sabbaticals parental leave number ofnew benefit plans changes exist men women childcare facilities ing plans approved past year arrangements help reconcile needs women percentage total workforce percentage women management positions number women top positions percentage women among candidates top management positions business report commitment employees career familyall measures comply local legislation many cases go far beyond legal requirementsroche offers option parttime employment wherever requirements ofthe job permitapproximately ofour current employees work parttime basis men respecting human rights roche supports respects human rights defi ned united nations applies princi ples consistentlythe compliance officer monitors policy throughout roche groupand serves contact person employeesfurther infor mation topic found wwwroche comenhomesussussoccommhumhtm two violations employment policy principles reported roche executive committee compliance officer soon violations became knownmeasures taken deal appropriately business report commitment society brief gains involvement society whole key prerequisite longterm orientation researchbased company roche operates success business regard specific according business model focuses aptitude finding innovative efficient solu creating sustainable added value principal tions unmet medical needs principal stakeholders rather maximising shortterm contribution societywe also contribute substan roche international committee red cross develop partnership gilles carbonnier head private sector relations icrc geneva switzerland roche international committee red cross icrc initiated new partnership october involve roche one seven swiss companies icrc developing longterm strategic partnership tackle various social issues around globe next six years roche support icrc fin ancially provision materials eg roche icrc working together drugs services even agreement combat aids though roche icrc cooperated various another area cooperation makes sense projects providing assistance victims question protecting victims wars tsunami catastrophe december natural catastrophes aids also occasion roche sent icrc antibiotics ensuring safety people icrc medicines treat people employees working countries large part africa roche helped us areas roche icrc work instance putting us touch main players together fight aids west africa instance exchanging ideas icrc bene fit substantially knowledge roche employ partnership develop going forward ees dealing medicines late april near future examining ways reinfor icrcs leading pharmacists came basel cing links possible areas personnel able see drugs manufactu management risk management logistics theres red sterile conditions important still lot potential cooperation icrc purchase drugs world roche icrc want certain buy good quality include counterfeits may deleterious health business report commitment society tially creating value main stakeholder saharan africathe price reductions hiv pro groups seeking maintain enhance ope tease inhibitors roche apply rating environment conducive innova people hivaids world tion strategies implemented roche improve global additionroche maintains supports num access healthcare include ber ofactivities closely bound developing clear patent pricing policy specialist skills particular business model aimed facilitating access hiv medication societal contexttoowe attach importance poorest people world make cooperating reliable partners focus around people worldwide living limited number sustainable effective pro hivaids jects roches position social responsibility working partnership committed govern currently undergoing review process due mentsnongovernmental organisations oth release er parties sharing similar goals undertaking research development develop new antihivaids medicines ensuring access healthcare improve existing ones worldwide promoting education training knowledge sharing roches important contribution society lies donating technical expertise area ofindus research development production trial development ofmedicines andin particular innovative costeffective solutions unmet ofantimalarials order support develop medical needsaccordinglyroche focuses areas ment distribution new drug combat company create genuine sustainable malaria added value result special expertise role healthcare system corporate cul find detailed information ture nurturedby developing main brochure committed making differencepub taining innovative solutions collaboration lished see also p information competent local partnersit often possible pro found wwwrochecomcommdiffreppdf vide lasting assistance designed deal well wwwrochecomenhomesustainability causes disease based simple susmedhtm wwwrochehivcom methodsthis applies especially programmes benefit groups least developed coun amplicare programme roche diagnostics tries defined united nations supplies subsaharan africa including south poorest need greatest africa well countries classified un wherein many casesaccess even fundamentals least developedcountries hivb load tests food drinking water basic lowest possible prices medical care guaranteed fight hivaids one example programme amplicare programme works together medicines focal point sustain laboratories clinics provide tailored able developmentthe distribution ofthe two hiv solutiondetermining products protease inhibitors invirase viracept may affordable suited region questionwe regarded exemplary roches policy roche dealing pharmaceutical prices offers medicines noprofit prices roche costs reflect range outlaysincluding basel least developed countries sub testsinstrumentsconsumablestraining logis business report commitment society tics services offer thus vary according tradition commitment sponsorship customers differing needs depending donations dividual requirementsthese costs may percent standard price owing areas expertise corporate amplicare initiative cooperating culturewe mainly involved usbased william j clinton presidential humanitarian social projects focused foundation developing world promoting sciencemedicine professional details please see brochure commitment developmentofyoung scientists areas care across globe information contemporary art cultureas well also available wwwrochecompagesdownloads local community environmental projects sustainpdfrochehivbroepdf since difficult ascertain sustainability monetary product donations dona tions kindroche decided publish detailed figures monetary value ofits activi tiesin roche donations went humanitarian social projects donated funds supported advancement sci ence educationnearly donations went projects contemporary culture arts community environmental projects onequarter donations made kind threequarters form financial support roche makes political donations clearly defined exceptional cases line prevailing legal ethical standardssuch donations made politi cal organisations support conditions favour innovation individualspolitical donations account donations sponsorship expenditurein roche began col lecting data impact monetary product donations first results one million patients benefited directly donations especially humanitarian social nature roche agreed donate million packs tamiflu world health organisation details see p last year roche maintained contacts business report commitment society ngos impressive proof policy authorities aid organisations organised working reliable partners fulfil emergency assistance conjunction inter commitments society people national relief bodiesin countries affected enjoyed support roche tsunami roche supplied medicines donations promote science educationcom treatment people find munity environmental projectsand culture information roche drug donations policy wwwrochecompagesdownloadssustain providing disaster relief roche supplies know pdfdrugdonpolpdf andwhere appropriateits products services competentlocally rooted aid organisa least ofthe founders familyroche tions order alleviate acute emergencies long intensive relationship contem decision undertake kind action lies porary art culturein particular music also local affiliateboth beginning fol demonstrated tinguely museumwhich lowing tsunami disaster asia donated maintained roche visu earthquake pakistan october roche al arts architecturethe rochenjazz project assessed situation together relevant example ofa new kind ofactivityset general managers touch local aim enable roche companies stage support roche research foundation founded roche rrf support totalling million swiss wwwresearchfoundationorg provides support young scientists francs paid projects conducting basic research biology applications swiss national medicine science foundation rrf thus countrys important institution supporting young scientists roche organ transplantation roche donating million swiss ten projects europe south research foundation wwwrotrforg francs within tenyear period america united states independent research foundation australia foundation money foundation supported grants totalling supports innovative research projects million swiss francs field organ transplantation roche foundation founded roche total million swiss francs anemia research undertake research new paid seven projects switzerland wwwrofarorg approaches treatment germany uk usa anemia applications genentech foundation support educational total million us dollars donated biomedical sciences communitybased organisations projects wwwgenecomgeneabout san francisco bay area usa communitygfbs business report commitment society global roche employee aids walk global roche employee aids walk sponsored walk involving roche employees world principle simple effec tive employees register walk encourage colleagues friends family members sponsor roche doubles sum collected employees money donated used support aids orphans malawi africa half million child ren lost one parents aids million people around world infected first aids walk took place roche hiv million live subsaharan sites basel switzerland nutley palo alto africa malawi approximately adults usa first year employees took part infected hiv malawi classified one event walked total least developed countries peaceful swiss francs aids orphans malawi politically stable country stability means already sites participating num projects put forward roche employees plan ber taking part increased tenfold time ned long term longterm planning essen employees joined donating approxima tial bringing sustainable improvement tely swiss francs children malawi orphans situation donations invested directly projects without held bureaucracy april seven successful roche fund managed partner organisation roche raisers travelled malawi see first hand european coalition positive people ecpp donations put use return thanks roche donations organisation convinced donations used able build orphanages directly benefit orphans one participant said children receive food clothing donations helping provide hope future benefit school education children business report commitment society series concerts partnership local jazz clubs series intended primarily roche employees families open interested members public wellit also designed promote local jazz performers composerswwwrochenjazznet ofcontributions employees augment ed roche contributions cases coordinated roche employee action charity trust react founded trust headquartered basel future co ordinate emergency measures longerterm recon struction programmes distribution funds collected aids walk business report business report avastin opening new era cancer therapy hamish hutchinson diagnosed advanced bowel cancer january first noticing abdominal discomfort around christmas exploratory surgery established extent cancer affected part hamishs colon successfully removed together surrounding tissue containing secondary tumour hamish started chemotherapy february one session avastin added treatment regimen august cycles chemotherapy plus avastin ct scan showed clear cancer treatment stopped hamish feels well enough live normal life returned work anesthesiologist hospitals tunbridge wells uk told advanced cancer came huge shock hamish family first reaction total disbelief support wife helen pleased get cancer two daughters clear doctor pollyanna victoria played big role able return work recoverythanks says hamish never gave therapy avastin bevacizumab opening new era cancer therapy offering patients better outcomes greater hope standard chemotherapy alone treatment metastatic colorectal cancer avastin first antiangiogenic drug demonstrated anticancer benefit inhibits growth network blood vessels supply nutrients oxygen cancerous tissues thus shutting blood supply essential growth cancers spread parts body business report safety health environmental protection corporate policy field safety health environmental protection apply health environmental protection throughout group division eco delegate supports organisation con roche gears corporate policy field ofsafe crete projectsfurther information found ty health environmental protection wwwrochecom enhomesustainabilitysusenv iso environmental management systems susenvpolhtm policy based experience going back many years commitment sus thanks professionalism hard work ofthe tainable development entered staff involved roche company fined context charter international cham significant amount infringements safety ber ofcommerce iccthe world business coun health environmental regulations cil sustainable development wbcsd evidently accomplished without resorting chemical industrys responsible care programme rigid management systems consume consider roche guidelines assurance safety able resources intention attain iso key figures investments millions chf operating costs millions chf occupational accidents workrelated fatalities workrelated accidents per million working hours workdays lost due workrelated accidents total number workdays occupational illnesses occupational illnesses per million working hours workdays lost due occupational illnesses occupational accidents contractor firms workrelated accidents per million working hours contractor firms number transport accidents road transport accidents per metric ton transported road x x total energy consumption tjyear co tyear tyear x tyear vocs tyear particulate matter tyear water consumption million cubic meters per year toc tyear heavy metals tyear chemical waste tyear fulltime personnel total number employees based cefic health safety environment reporting guidelines november business report safety health environmental protection andor emas certification centrally nevertheless management systemcorporate safetyhealth approximately nine local manufacturing compa environmental protection cse carrying nies representing oftotal production volume systematic groupwide audits company chemical production volume sites since date nearly decided discretion adopt completed year review total approachbased existing corporate policies production facilitiesdistribution centresresearch sites office buildings audited coun auditing triesonce againthe results good safetyhealth environmental protection audits audits focused primarily safe envi audits key element roche ronmentally responsible behaviour ofemployees energy consumption reduced percent palo alto california keith sonberg team busy translating roche energy con servation policy action result lower energy consumption lower costs keith sonbergs team proud awardwinners ecompetition roche competition sustainabi lityrelated ideas award project reduced energy consumption laboratory fume hoods savings come us dollars year fume hood think competition laudable idea says sonberg clearly shows roche mana gement aware sustainability environmental issues addition fume hood project sonberg rudolf schwob roche corporate safety health team palo alto developed imple environmental protection explains criteria mented comprehensive sustainability programme projects awarded competition prizes ranging energysaving light bulbs green counted projects impact engineering employee training environment also budget also important projects could implemented results impressive past three years roche sites well energy consumption palo alto site reduced percent water consumption roche employees given chance parti percent recycling rate construction waste cipate competition submitting projects high percent sonberg says improve sustainability working environment pride roche listed right dow third time ecompetition held follo jones sustainability index goal remain wing competitions total pro environmentally friendly economically effective jects submitted selected socially accountable future jury prizewinners business report safety health environmental protection workplaceas well technical safety number ofoccupational illnesses per million work processes plantsthe risk ofdust explosions ing hours increased well number ofwork production formulation well hazards ing days lost result occupational illnesses handling biologically active compounds line growth ofthe company terms potentially contaminated diagnostic instruments headcount number sites well produc become increasingly important aspects ofrisk tion volumeenergy consumption increased assessment absolute figures efficiency improved relation sales revenue number employees systematic audits ofstrategically important suppli true volume greenhouse gas ers manufacturing chemical intermediatesfinished emissions emissions air water products exclusive equipment parts also declinedas volume ofchemical waste performed ofthese audits completed past year scope reporting year reporting covers roche group pharmaceuticals diagnostics divi sions well chugai genentechas scope ofthe reporting previous year key figures directly comparable even absolute terms owing different system boundaries possible earlier years bulk data collected november basis ten months extrapolated entire year costs well accidents incidents fullyear data collected details safety health environmental protection please see wwwrochecomenhomesustainabilitysusenvsus envcarehtm results brief groups performance published part sustainability report third year successionfor ten years previously published separate reportthe groups performance described good whole trend achieving goals set energy consumption greenhouse gas voc emissions pointing right directionnew targets intended spur roche group improve performance reports throughout entire group significant damage affected either individuals environment number occupational accidents kept low levelthe business report safety health environmental protection goals progress safety health improvement ecobalance environmental protection indicator also recorded year first time roche set target reducing reduction consumption per groups greenhouse gas emissions ieco employee line energysaving energy generation halogenated hydrocarbons goal air conditioning equipment chillers annual targetno relevant fines area percent within five years period energy consumption ecoefficiency expenditure emissions volatile organic compounds voc safety health environmental reduced percentageabso protection lute values based group sales order allow changes corporate structure ecoefficiency enable comparisons made baseline ecoefficiency important element promo ting sustainable development ecoefficient pro owing various measures reduce emissions duction processes conserve resources raw positive trend group sales revenuethe tar materials energy reduce impact gets set already reachedroche environment decreasing emissions waste determined make efforts confirm volumesthere also positive financial impact improve good results roche quantifies ecoefficiency calculating ecoefficiency rate eerthe eer indicator goals ecological effect expenditure en vironmental area determined means readily measurable parameters quantities energy consumption ofsubstances emitted waste produced well financial figures sales spending ear marked environmental protection higher greenhouse gas emissions eer greater degree ecoefficiency details see wwwrochecomenhome sustainabilitysusenvsusenvcarehtm voc emissions expenditure goals roche group purposes graph values normalised sales investments safety health given multiplier factor energy consumption x greenhouse environmental protection gas emissions x voc emissions x operating costs additional objectives defined total expenditure within framework medium longterm millions chf programme reduction roche accident rate ecobalance rar reduction absences overall achieve target ofa improvement relevant indicator recorded year groups ecobalancea criterion must established first time compared number yearsfor business report purposeroche employs method ofthe swiss agency environment bafu environmental impact points given ecologi cally relevant parameters emissionswaste energy consumption points added expressed function number employees past year ratio figure serves baseline measuring improvements investment operating costs expenditure roche group totalled million swiss francs amount compris investments investments e investments operating costs total expenditure safety health environmental protection ecoefficiency rate eer including chugai genentech sales environmental expenditure environmental damage eer millions chf millions environmental damage units key figures ecoefficiency including chugai genentech including sources co emissions external energy generation hence comparable previous years key figures unit energy tj million sales co million sales voc million sales water million sales toc million sales chemical waste million sales es investments made various areas well operating coststhe calculation investments takes account full value con struction projects solely purpose egfire extinguisher systemswastewater treatment waste incineration plants portion investment calculated arising projects new production facilities plantsin investments amounted mil lion swiss francs environmental protection million swiss francs safety health operating costs year review amounted million swiss francsthis inclu expenditure millions chf business report safety health environmental protection des current spending services personnel accident statistics costs area shein total number roche group employees working fulltime employees roche group roche group expenses expressed employees recorded statistics proportion oftotal sales workdays lost workdays recorded occupational accidents recorded safety health protection occupational accidents employees accidentsmillion working hours cefic roche believes important employees work healthy safe working environ rar roche accident rate ment possible safety health committees see glossaryexplanatory notes wwwrochecomen focus technical activities production homesustainabilitysusenvsusenvcarehtm laboratories workshops introduced virtually roche subsidiaries cover employees given site part ofhealth monitoring programmesmotivating staff increase level physical activity increasingly using workplace way providing information healthy nutrition reaching employees order help roche began collecting data general prevent potential workrelated problems also absences aim discover something enhance staff health general initiatives causes absences seek possible include offering preventive medicine measures improvements working highly active substances recent pharmaceutical research produced medi cines even specifically targeted biological action fit precisely particular receptors without influencing targets targeted action often effective even minuscule quan tities case called highly active compounds substances however potent patients manufacturing essential ensure employees overexposed substances care must taken contaminate prod ucts highly active substances processed contained systems workplace special emphasis placed technical within roche industrial hygiene committee con approach ie contained systems sisting specialists occupational toxicity industrial roche decided build completely new plant hygiene occupational medicine prepares assess meeting necessary technical standards ments hazards posed substance manufacture drugs containing highly active sub defines exposure limits serve tool stances chose erect new plant toluca derive appropriate protective measures mexico business report occupational accidents accidents per employees roche group figures occupational accidents roche deteriorated slightly though low level year reviewthe number ofaccidents involv ing roche employees rose severity accidents ie number working days lost per accident result accidents increased roche accident rate rar rose addition roche employees total employees contractor firms involved accidents ie previous year figure parallels number ofcontractorswho past year worked mainly construction sector occupational illnesses total number ofoccupational illnesses reported increased working days lost result illness year review types illnesses reported last years remained unchangedlocomotor disor ders continue common back problems especially inflamma tion upper extremities caused repetitive movementsillnesses relating use chemi cals limited allergiesthere werehoweverno cases ofintoxication incidents incident accident significant impact people environment reported anywhere roche groupowing small number minor incidents statistical analysis events virtually impossible nevertheless human error identified main cause transport previous yearsroad transport accounted bulk goods moved followed air transport two incidents reported lorry loaded pharmaceu tical active substance stolen cargo another lorry destroyed result acci dent roche accident rate rar safety health environmental protection occupational illnesses roche group recognised cases occupational illnesses lost working days various transport modes shown percentage road rail sea air inland waterways business report safety health environmental protection environmental protection energy consumption sustainable development also implies responsible use resource energyroche therefore set two goals reducing energy consumption companyalongside corporate target reducing energy consumption relation sales within five years additional longerterm goal formulated reduce consumption relation head count period close correlation energy consumption co emissionsa decrease energy consumption therefore lead reduction release ofgreen house gases atmosphere year reviewthe roche group needed terajoules ofenergy various sources natural gas oil coal waste renewable energy electricity district heating fleet vehicles business travel air total run operationsthis figure includes energy required run group companies fleet vehicles well energy consumed business travelin absolute termsconsumption thus risen yearonyearhoweveruse per employee actually fallen greenhouse gases roche supports efforts international communityas laid kyoto protocolto adopt worldwide approach controlling global business report warming greenhouse gases res ponsible groupwide target decrease emissions relation sales measures already reached trading emissions certificates cur rently option us unlikely become foreseeable future greenhouse gas emissions measured accor dance greenhouse gas protocol serves gri standard requires us account direct emissions power generation fossil fuels waste incineration fleet vehi clesbusiness travelwastewater treatment well imported energy electricity greenhouse gas emissions roche mostly consist co power generation direct emissions combustion fossil fuels account halfofco outputapproximately ofall energy consumption figures tj joules emissions comes co resulting imported energy particular electricity roche responsible co emissions amounted metric tons halogenated hydrocarbons play smaller role greenhouse gas emissionsthey used cooling air conditioning installations well fire extinguishing equipmentin emissions amounted metric tonsthe global warming potential ofhalogenated hydrocarbons converted co equivalentsusing conversion factors specific contribution anthropogenic greenhouse effect roche group co emissions combustion co equivalents halogenated hydrocarbon emissionst co equivalents total sales swiss francs millions co equivalents million francs sales mean global warming potential halogenated hydrocarbons based recalculation using conversion factor ipcc halogenated hydrocarbon emissions halogenated hydrocarbon inventory safety health environmental protection stipulated intergovernmental panel fall inventory ofthese compounds compared climate change ipcc added total previous year illustrates progress made quantity ofco emissions implementing guidelines roche climate strategy prescribes measures greenhouse effect roches contribution lower emissions areas close link power generation co output means calculate roches exact contribution energy saving measures automatically lead greenhouse effect expressed co equivalents reduction co emissionscorporate guide per million francs sales greenhouse gas emis lines exist relation use halogenated sions sales serve benchmarks hydrocarbons cooling systems outlining results value ofrepresenting improve gradual phasingout use ment co emissions tyear natural gas oil coal waste imported energy fleet vehicles business travel air wastewater treatment total co business report safety health environmental protection waste volume waste chemical pro duction amounted metric tonsofwhich metric tons incinerated rest including inert substances incineration residues slag ash also sewage sludge deposited landfills waste byproducts metric tons residual substances cycled total general waste came metric tons metric tons construction wastethe majority ofwhich deposited landfillsa total metric tons ofgeneral waste deposited landfills incineration landfill construction debris total landfilled total recycling business report general waste figures tyear chemical waste figures tyear incineration landfill total valorised general waste metric tons per year roche group incineration landfill construction waste total recycling chemical waste metric tons per year roche group incineration landfill total valorisation safety health environmental protection contaminated sites responsibility originator industrial activities leave traces subsoil soon contaminated site brought atten sites question substances used installations tion authorise studies required evaluate chemicals manufactured processed often associated risks depending outcome steps leave residues soil addition nature containment necessary remediation site synthesis pharmaceutical substances results subsequently taken process conducted close desired substance also byproducts collaboration competent authorities ultimately disposed chemical compliance current legislation waste past lack knowhow appro priate technical resources meant landfill dumping solely responsible contami disposal method choice approach nated site landfill promptly conducted governed legislation result various investigation taken necessary remediation local authorities made suitable plots land measures thus example number contami available charge often joint use number nated sites originating companies prior companies acquisition roche remediated conver sely roche continues assume responsibility improved knowledge geological characteristics costs necessary remediation contaminated negative experiences leaking earth formations sites landfills arising connection vitamins led discontinuation landfills dis division sold bear costs posal chemical waste contaminated sites sub relating actions sizeable reserves ject increased monitoring thorough examination set aside purpose order evaluate associated risks initiate steps required containment remediation case landfill sites shared compa site question nies collaboration sought parties concerned order come solutions acceptable since roche always pharmaceutical com pany relatively low volumes chemical produc tion total quantities chemical waste share accept responsibility waste deposited deposits common landfill sites rule small roche sites landfills even method disposal widespread time based relevant legal requirements business report safety health environmental protection non halogenated vocs halogenated vocs total vocs x total inorganic wastewater organic carbon load measured total organic carbon toc wastewater treatment total metric tons discharged addition heavy metal discharges wastewater amounted metric tons business report atmospheric emissions metric tons per year emissions water air emissions roche responsible metric tons inorganic emissions form sulphur dioxide nitrogen oxides x substances result ofincineration processes energy generationair emissions soot parti culates dust came metric tonsemissions volatile organic compounds vocs came metric tonsofwhich contain halogens toc metric tonsyear heavy metals kgyearwater consumption reporting water consumption roche based gri water protocol million metric tons ofwater consumediewent product vaporised cooling air con ditioning systems million metric tons ofwaste water chemical production purified wastewater treatment plants million metric tons represented water cooling systems could returned receiving waters thor ough analysis without purification special chemicals halogenated solvents metric tons per year year review total metric tons halogenated solvents used roche production facilities laboratories methylene chloride accounted greater part ofthis total around production ofthe active substance used aids drug fuzeon accounted half total used higher consumption reported reflects increase production volume chloroform used small quantities laboratories compliance group directive roche affiliates supply figures regarding quantities use substances thatas precursor substances chemical weaponsdrugs narcoticsare subject international regulation quantities reported remained consistently low level num ber years compounds used manufacture roche products sub stances sold third parties safety health environmental protection water consumption million cubic metres per year roche group withdrawal various sources purified treatment plants returned receiving waters used consumption business report safety health environmental protection business report ive got independence back business report selfmonitoring lets patients get lives age alexander bcker nearly died school trip young german collapsed rushed hospital doctors discovered meningitis cerebral hemorrhagealexander survived speech severely impairedand episode also left requiring lifelong treatment bloodthinning anticoagulants meant report regularly doctor therapy monitored alexander quickly overcame speech impairment trained social care provider works predominantly people disabilitiestwo years ago regained even old independence thanks device thats scarcely bigger cell phone coaguchek salexander able monitor anticoagulant therapy eliminating need weekly trips doctor last year alexander went ninemonth roundtheworld trip took united statesaustralia new zealand japantravelling girlfriend companion made trip possible first placehis coaguchek monitoring patients anticoagulants monitor coagulation status closely keep dose right level time required trip hospital doctors office devices like coaguchek giving patients independence back enabling monitor treat ment business report assurance assurance independent assurance report roche tional framework standards assurance engage group sustainability reporting ments approved december interna tional auditing assurance standards board iaasb roche corporate sustainability committee planned performed evidencegathering engaged provide assurance procedures obtain basis conclusions sustainability reporting roche accordance international standard consolidated subsidiaries excluding chugai assurance engagements isae assurance genentech group year ended engagements audits reviews december performed evidence historical information approved december gathering procedures hereafter jointly referred iaasb subject matter key figures table entitled scope evidencegathering procedures important key figureson selected social dimension information assess roche staff apply group internal social dataand sustainability reporting guidelines site level management reporting prepara using sample five production sites covering tion ofthe report figures pharmaceutical diagnostics divisions test effectiveness ofthe internal sustainability evaluated subject matter reporting system used collect data following criteria evaluation criteria des social data group sites cribed observe compliance group internal sus roche group internal sustainability repor tainability reporting guidelines selected sites ting guidelines respect responsible care healthsafety environmental reporting perform specific procedures checkon sample guidelines published european chemical basisthe data social data industry council cefic sustainability reporting guidelines published evidencegathering procedures included global reporting initiative gri following work procedures data visiting selected sites austria south africa social data preparedcollated aggregated turkey us internallyand interviewing responsible stafffor data collec control environment accuracy tion sustainability reporting sites completeness ofthe data social data visited group level statement read conjunction assessing data consolidation process inherent limitations ofaccuracy complete group level ness sustainability dataas well connection reading performing tests ofthe relevant doc roche group internal reporting guidelines umentation sample basis including group explained scope reporting policies management reporting structures documentation systems used collectana lyze aggregate reported data social roche group responsible subject dataand matter evaluation criteria performing tests sample basis evidence supporting selected data social data responsibility report internal regard reported data aggregation reporting processesdataand key figures social selected sites group levelhowever dimension based evidencega performed site visits chugai thering procedures accordance interna genentech business report assurance opinion roche group internal sustainability reporting guidelines applied properly selected sites internal reporting system collect data functioning designedand social dimension reporting provides appropriate basis disclosure social dimension information material respects based evaluation criteria based work described reportnothing come attention causes us believe procedures data social dimension information prepared collated aggregated control environ ment selected sites based established accepted measurement analytical methods give fair picture ofthe social dimen sion performancein material respectsbased evaluation criteria pricewaterhousecoopers ag dr thomas scheiwiller jrg hutter zurich january business report track record outlook track record outlook objectives goals targets onwards achievements general remain top tier regarding increase internal external remain top quartile renewed inclusion transparency sustainability awareness improve posi indexes ratings within ftsegood djsi related activities tion external investigations healthcare sector new website launched revised website based first quarter stakeholder feedback sustainability topics inte expansion communication grated overall activities sustainability communication strategy internally externally sustainability included topic key internal corporate events establish roche business identification drivers establish implement workshop held members case sustainability business case monitoring process corporate measuring document business case divisional functions identify appropriate kpis define set relevant key key areas performance indicators kpis integrated operations section annual report sustain ability report form single business review ethics governance responsible management strengthen business ethics increase awareness high participation rate publication roche intranet awareness adherence roches corpo new elearning tool internet sites roche rate principles roches roches code conduct corporate principles together directives guidelines incidents roches directives guide regulations together lines policies regulations form roches code conduct form roches code conduct development new elearning tool ensure highest standards independent external body discussion controversial establishment clinical relation human subject review escalated ethical political ethical topics research ethical advisory research create issues clinical research ethi inclusion data group creag transparency regards cal advisory group creag phase iiiv trials established clinical trial pro clinical trials recognised leading products marketed since tocol registry results clinical trial protocol registry october database trials registered results database continue implementation new future retrospective contracts new contracts supply chain policy contracts aligned incorporate new policy incorporate roche supplier supply chain policy policy coordinate social environmental alignment see risk establishment clear pro responsibilities assessment ethical see risk assessment cedure assessing see risks see risks defined identification management group risk report process allocated rigorous management system focus risk assessment risk reduction measures audits business report track record outlook objectives goals targets onwards achievements ensure appropriate respon global coordinator system continuation audits revised animal welfare paper sible use animal resources introducedimplemented documentation global coordinator animal sites adjustment processes welfare identified sites aaalac accreditation proof accreditation roche research sites sustainability website conducting animals tests contribution society develop new health solutions produce medically differenti number new innovative key innovative launches unsolved health problems ated products either products launched avastin high medical need first class best class herceptin tarceva bonvivaboniva amplichip cyp improve access healthcare recognised top quartile monitor pricing clinical trial policies developed least developed companies ensuring access improved website least developed countries countries healthcare documentsbrochures subsaharan africa improve transparency rating reduction pricing roche activities area activities tiered pricing tamiflu corporate policyposition formal csr policy internally externally review process initiated corporate responsibility csr established csr policy philanthropy continuously updated reports csr activities sustainability website updating internal action plan regular transparent reporting stakeholder dialogue improve systematic identification key stake good results external published list memberships stakeholder dialogue holders established ratings key partners web communication channels establishment agenda stakeholder survey performed provide consistent defining responsibilities conditions created collec timely communication continuous reporting ting data ngo contacts stakeholders dialogue website valuing employees keep improve position recognised top tier good results peer review numerous awards employer choice employer industry relevant awards science fortune within healthcare industry maintain high level rela low rate regretted losses tionship within company part corporate culture business report track record outlook objectives goals targets onwards achievements safety health environmental protection reduce accident rate roche accident rate rar rar reduction vs reduce absence rate incl hemployee illness home accidents reduction vs reduce energy consumption gjemployee reduction vs improve total ecobalance pointsemployee improvement vs relevant fines fines relevant fines chf reduce ghg emissions co equivalentssales reduction vs reduce voc emissions tonnes vocsales reduction vs develop strategy position public position key position contaminated sites key topics related topics public interest issues matters business report key performance indicators key performance indicators economic business performance sales continuing operations chf millions ebitda continuing operations chf millions operating profit exceptional items chf millions net income chf millions core earnings per share diluted chf research development chf millions research development sales contacts stakeholders dividends distributed chf millions taxes paid chf millions personnel costs chf millions patients participating clinical trials available patients benefiting donations available commitment employees newly created positions number employees women percentage women management positions fluctuation number training hours per employee percentage country affiliates local general manager safety health environmental protection investments millions swiss francs operating costs millions francs workrelated accidents per million working hours workdays lost due workrelated accidents occupational illnesses per million working hours workdays lost due occupational illnesses workrelated accidents per million working hours contractor firms total energy consumption tjyear co tyear tyear x tyear vocs tyear particulate matter tyear water consumption million cubic meters per year toc tyear heavy metals tyear chemical waste tyear business report gri reference list gri reference list vision strategy reportremarks statement organisations vision cid pages strategy regarding contribution sustainable development statement ceo cid profile organisational profile name reporting organisation cid cid major products andor services cid cid pages operational structure organisation cid cid description major divisions cid operating companies subsidiaries joint ventures countries organisations operations located cid cid nature ownership legal form cid nature markets served cid cid pages scale reporting organisation number employees cid cid products producedservices offered quantity volume cid net sales cid cid total capitalisation broken terms debt equity cid addition reporting organisations encouraged provide additional information value added cid total assets cid breakdowns following salesrevenues countriesregions make percent cid according region detail total revenues major products andor identified services cid products highest sales pages costs countryregion cid employees countryregion cid cid list stakeholders key attributes cid relationship reporting organisation report scope contact persons report including email web addresses cid reporting period eg fiscalcalendar year information provided cid date recent previous report cid boundaries report specific limitations scope cid significant changes size structure ownership cid cid productsservices occurred since previous report basis reporting joint ventures partially owned subsidiaries cid based cefic required parameters shown leased facilities outsourced operations situations significantly affect comparability period period andor reporting organisations explanation nature effect restatements information cid provided earlier reports reasons restatement report profile decisions apply gri principles cid protocols preparation report criteriadefinitions used accounting economic cid environmental social costs benefits significant changes previous years cid cid measurement methods applied key economic environmental social information policies internal practices enhance cid provide assurance accuracy completeness reliability placed sustainability report policy current practice regard cid providing independent assurance full report means report users obtain additional information cid reports economic environmental social aspects organisations activities including facilityspecific information available business report gri reference list governance structures management systems reportremarks structure governance governance structure organisation cid cid pages percentage board directors independent cid cid nonexecutive directors process determining expertise board members need guide cid cid strategic direction organisation including issues related environmental social risks opportunities boardlevel processes overseeing organisations identification cid pages management economic environmental social risks opportunities linkage executive compensation achievement cid cid organisations financial nonfinancial goals eg environmental performance labour practices organisational structure key individuals responsible oversight cid cid implementation audit economic environmental social related policies mission values statements internally developed codes cid pages conduct principles polices relevant economic environmental social performance status implementation mechanisms shareholders provide recommendations cid cid direction board directors stakeholder engagement basis identification selection major stakeholders cid approaches stakeholder consultation reported cid terms frequency consultations type stakeholder group type information generated stakeholder consultations cid use information resulting stakeholder engagements cid overarching policies management systems explanation whether precautionary approach cid principle addressed organisation externally developed voluntary economic environmental cid pages social charters sets principles initiatives organisation subscribes endorses principal memberships industry business associations cid andor nationalinternational advocacy organisations policies andor systems managing upstream downstream impacts including supply chain management pertains outsourcing cid supplier environmental social performance product service stewardship initiatives cid reporting organisations approach managing indirect economic cid environmental social impacts resulting activities major decisions reporting period regarding cid location changes operations programmes procedures pertaining economic environmental social performance include discussion priority target setting cid major programmes improve performance cid internal communication training cid performance monitoring cid internal external auditing cid pages senior management review cid status certification pertaining economic environmental cid social management systems gri content index table identifying location element gri report cid content section indicator business report gri reference list economic performance indicators reportremarks customers ec net sales cid cid ec geographic breakdown markets cid cid pages suppliers ec cost goods materials services purchased cid ec percentage contracts paid accordance cid principal contract carried agreed terms according agreed terms employees ec total payroll benefits cid cid capital providers ec distributions providers capital cid ec increasedecrease retained earnings end period cid public sector ec total sum taxes types broken country cid cid total income taxes shown broken country ec subsidies received cid ec donations cid roche currently issue global figures limited significance environmental performance indicators material en total materials used water type cid production individual pharmaceutical substances takes place using completely different syntheses many different places different times figure continuity value estimation environmental performance en percentage materials used wastes cid see remarks en energy en direct energy use cid en indirect energy use cid en initiatives increase energy efficiency cid pages en indirect energy use cid water en total water use cid biodiversity en biodiversityrich habitats cid relevant roche business en impacts biodiversity cid ecotoxicological material data intermediate end products prepared published report emissions effluents waste en greenhouse gas emissions cid pages en use emissions ozonedepleting substances cid en significant air emissions typen cid x en total amount waste cid en significant discharges water type cid en significant spills chemicals oils fuels cid products services en significant environmental impacts cid environmental risk assessments principal products services prepared active substances published report en recyclable products cid valorised byproducts recycled solvents compliance en fines noncompliance cid en total environmental expenditures type cid social performance indicators employment la workforce cid la net employment creation average turnover cid pages labourmanagement relations la percentage employees represented cid la policy procedures involving information cid consultation negotiation employees changes business report gri reference list health safety reportremarks la occupational accidents diseases cid la health safety committees cid la key figures injury lost day absentee rates cid pages workrelated fatalities la description policies programmes hivaids cid see wwwrochecomhomesustainabilitysussoc sussoccommhtm training education la average hours training per year per employee cid diversity opportunity la equal opportunity policies programmes cid la composition senior management corporate governance bodies cid cid pages including board directors la employee benefits cid cid cid locally arranged according performance local business human rights strategy management hr prevention discrimination business activities cid cid procedures deal human rights hr human rights investment procurement decisions cid cid hr human rights supply chain cid cid pages nondiscrimination hr prevention discrimination business activities cid cid freedom association collective bargaining hr principles freedom association policy cid cid child labour hr principles regarding exclusion child labour cid cid forced compulsory labour hr guidelines prevention forced compulsory labour cid cid social guidelines communitiescompanies description policies manage impacts communities areas cid general guidelines defined locally affected activities well description proceduresprogrammes local companies guidelines address issue including monitoring systems results monitoring awards received relevant social ethical cid environmental performance bribery corruption guidelines addressing bribery corruption cid political support guidelines managing political lobbying cid general guidelines contribution directed local arrangements competition pricing court decisions pertaining antitrust monopoly regulations cid guidelines prevention anticompetitive behaviour cid product responsibility consumer health safety pr guidelines preservation customer health safety cid principles covered pharma ceutical industry great extent national international laws guidelines products services pr guidelines product information labelling cid principles covered pharma ceutical industry great extent national international laws guidelines respect privacy pr guidelines consumer privacy cid principles covered pharmaceuti cal industry great extent national international laws guidelines indicator detailed data report indicator covered report detailed data fully available indicator apply roche data submitted published report data available found finance report material violations business report sales manufacturing overview switzerland czech republic argentina denmark australia dominican republic austria ecuador bangladesh el salvador belgium estonia bermuda finland brazil france canada germany chile great britain china greece colombia guatemala costa rica guernsey business report roche global market presence roche global market presence research development services financing toll manufacturing third parties honduras netherlands singapore hungary new zealand slovenia india nicaragua south africa indonesia norway south korea ireland pakistan spain italy panama sweden japan peru taiwan latvia philippines thailand lithuania poland turkey luxembourg portugal uruguay malaysia romania usa mexico russia venezuela morocco serbiaand montenegro business report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing new products new uses corporate sustainability committee existing products including without limitation pierre jaccoudchair negative results ofclinical trials research projects tel unexpected sideeffects pipeline marketed emailpierrejaccoudrochecom products increased government pricing pres sures interruptions production loss order publications orinability obtain adequate protection intel tel lectual property rights litigation loss fax key executives employeesand adverse emailbaselwebmasterrochecom publicity news coverage statement regarding earnings per share growth profit forecast inter preted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share ofroche next annual general meeting february trademarks mentioned enjoy legal protection roche annual report published german original language english printed nonchloride bleached paper roche annual report issued f hoffmannla roche ltd basel corporate communications business report